

10/520142

**REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING  
EXPRESSION OF TUMOR SENESENCE GENES**

5                                   **BACKGROUND OF THE INVENTION**

          This application was supported by a grant from the National Institutes of Health,  
No. \_\_\_\_\_. The government may have certain rights in this invention.

10    1.     **Field Of The Invention**

          This invention is related to changes in cellular gene expression and compounds  
that produce changes in cellular gene expression. In particular, the invention is related to  
the identification of genes the expression of which is associated with the development of  
senescence in mammalian tumor cells upon treatment with cytotoxic agents, including  
15   chemotherapeutic drugs, such as doxorubicin, and ionizing radiation. More specifically,  
the invention provides methods for identifying compounds that modulate expression of  
these cellular genes. The invention also provides reagents that are recombinant  
mammalian cells containing recombinant expression constructs that express a reporter  
gene under the transcriptional control of a promoter for a senescence-associated gene  
20   expression, and methods for using such cells for identifying compounds that modulate  
expression of these cellular genes and produce senescence in said cells. Compounds  
identified using the methods of the invention are provided for use in therapeutic methods  
for treating diseases and disorders relating to abnormal cellular proliferation or neoplastic  
cell growth. Diagnostic methods, particularly methods for monitoring the efficacy of  
25   anticancer treatment regimes, are also provided by this invention.

          2.     **Summary Of The Related Art**

          Cancer remains one of the leading causes of death in the United States. Current  
treatment for cancer includes chemotherapy and radiation, but these treatments are not  
30   invariably cytotoxic to all tumor cells. Some of the cells that survive treatment recover  
and resume proliferation, while others undergo permanent growth arrest. Irreversible  
proliferation arrest in tumor cells treated with anticancer agents may result from cell  
death or permanent growth arrest. Although the mechanism of damage-induced cell  
death is a subject of active investigation, little is known about the determinants of

terminal growth arrest in tumor cells.

Exposure of different tumor cell lines to various anticancer agents *in vitro* and *in vivo* induces long-term growth arrest with phenotypic features of cell senescence, such as cell enlargement, increased adhesion and granularity, and senescence-associated  $\beta$ -galactosidase activity (SA- $\beta$ -gal; Chang *et al.*, 1999a, *Cancer Res.* 59: 3761-3767). Induction of the senescent phenotype in treated tumor cells has been observed in cells treated with a variety of cytotoxic agents, such as doxorubicin, aphidicolin, cisplatin, ionizing radiation, cytarabine, etoposide or taxol; this response is detectable in treated tumor cells even at the lowest concentration of a cytotoxic agent that produces detectable growth inhibition (Chang *et al.*, 1999a, *ibid.*). Senescence of tumor cells can be produced upon treatment not only with cytotoxic agents but also with vitamin A derivatives, retinoids, under conditions that produce growth inhibition with only minimal cytotoxicity (Chang *et al.*, 1999a, *ibid.*). Retinoid-induced senescence in breast carcinoma cells is associated with co-induction of several growth-inhibitory genes, as described in Dokmanovic *et al.* (2002, *Cancer Biol. Ther.* 1: 16-19) and in co-owned and co-pending U.S. Serial No. 09/865,879, filed May 25, 2001, incorporated by reference herein. Tumor cells can also be induced to undergo senescence through ectopic expression of tumor suppressors (Sugrue *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 9648-9653; Uhrbom *et al.*, 1997, *Oncogene* 15: 505-514; Xu *et al.*, 1997, *Oncogene* 15: 2589-2596) or oncogene inhibition. For example, inhibition of papillomavirus oncoproteins E6 and E7 in cervical carcinoma cell lines was found to induce senescence-like growth arrest in almost 100% of cells (Goodwin, 2000, *Proc. Natl. Acad. Sci. USA* 97: 10978-10983). Activation of the senescence program in tumor cells appears therefore to be a feasible biological approach to cancer therapy.

There remains a need in the art to identify genes that are induced when a cell, particularly a tumor cell, becomes senescent, both as markers for the senescence phenotype and as targets for inducing senescence in said cells. There is also a need in the art to identify cells, particularly tumor cells that have become senescent in response to treatment, particularly anticancer treatment, to assess the efficacy of such treatment. There is further a need in the art to identify compounds that induce senescence in mammalian cells, particularly tumor cells, as a way to improve treatment of proliferative disorders such as cancer.

### SUMMARY OF THE INVENTION

This invention provides genes that are induced or repressed in senescent cells and arise upon treatment with cytotoxic agents, as well as reagents and methods for identifying compounds that induce or repress such genes. The invention also advantageously provides compounds that mimic the effects of cytotoxic agents in inhibiting the growth of tumor cells without producing toxicity associated with these agents. Most preferably the mimicked effect is induction of senescence in mammalian tumor cells.

In a first aspect, the invention provides a method for identifying a compound that induces senescence in a mammalian cell. In one embodiment, the method comprises the steps of culturing the mammalian cell in the presence and absence of the compound; assaying expression of at least one cellular gene set forth in Table 2A in said cell in the presence of the compound with expression of said gene in the cell in the absence of the compound; and identifying compounds that induce senescence when expression of at least one cellular gene in Table 2A is higher in the presence of the compound than in the absence of the compound.. In a preferred embodiment, the mammalian cell is a p53 deficient cell. In other preferred embodiments, the mammalian cell is a tumor cell. Preferably, the cellular gene is a human gene, most preferably BTG1, BTG2, EPLIN, WIP1, Maspin, MIC-1, IGFBP-6 or amphiregulin. Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.

In alternative embodiments, the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a cellular gene in Table 2A. In these embodiments, induction of at least one of the cellular genes in Table 2A is assayed using the recombinant mammalian cell and increased expression of the reporter gene detected in the presence and absence of the compound. In further preferred embodiments, the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound.

Expression of reporter genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the reporter gene product.

5 In additional embodiments of the first aspect of the invention, the method for identifying a compound that induces senescence in a mammalian cell comprises the steps of culturing the mammalian cell in the presence and absence of the compound; assaying expression of at least one cellular gene set forth in Table 2A in said cell in the presence of the compound with expression of said gene in the cell in the absence of the compound; assaying the recombinant mammalian cell for cell growth and morphological features of  
10 senescence; and identifying compounds that induce senescence when expression of at least one cellular gene in Table 2A is higher in the presence of the compound than in the absence of the compound and the cells are growth-inhibited and express morphological features of senescence in the presence of the compound. In a preferred embodiment, the mammalian cell is a p53 deficient cell. In other preferred embodiments, the mammalian  
15 cell is a tumor cell. Preferably, the cellular gene is a human gene, most preferably BTG1, BTG2, EPLIN, WIP1, Maspin, MIC-1, IGFBP-6 or amphiregulin. Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.

20 In alternative embodiments, the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a cellular gene in Table 2A. In these embodiments, induction of at least one of the cellular genes in Table 2A is assayed using the recombinant mammalian cell and increased expression of the reporter gene detected in the presence and absence of the compound. In further preferred  
25 embodiments, the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound. Expression of reporter genes according to the method is preferably detected by  
30 hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the reporter gene product.

In a second aspect, the invention provides a method for identifying a compound that induces senescence in a mammalian cell. In one embodiment, the method comprises the steps of culturing the mammalian cell in the presence and absence of the compound; assaying expression of at least one cellular gene set forth in Table 1 in said cell in the presence of the compound with expression of said gene in the cell in the absence of the compound; and identifying compounds that induce senescence when expression of at least one cellular gene in Table 1 is lower in the presence of the compound than in the absence of the compound. In a preferred embodiment, the mammalian cell is a p53 deficient cell. In other preferred embodiments, the mammalian cell is a tumor cell. Preferably, the cellular gene is a human gene, most preferably HFH-11, STEAP, RHAMM, INSIG1, LRPR1. Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.

In alternative embodiments, the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a cellular gene in Table 1. In these embodiments, induction of at least one of the cellular genes in Table 1 is assayed using the recombinant mammalian cell and decreased expression of the reporter gene detected in the presence and absence of the compound. In further preferred embodiments, the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound. Expression of reporter genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the reporter gene product.

In additional embodiments of the second aspect of the invention, the method for identifying a compound that induces senescence in a mammalian cell comprises the steps of culturing the mammalian cell in the presence and absence of the compound; assaying expression of at least one cellular gene set forth in Table 1 in said cell in the presence of the compound with expression of said gene in the cell in the absence of the compound; assaying the recombinant mammalian cell for cell growth and morphological features of senescence; and identifying compounds that induce senescence when expression of at

least one cellular gene in Table 1 is lower in the presence of the compound than in the absence of the compound and the cells are growth-inhibited and express morphological features of senescence in the presence of the compound. In a preferred embodiment, the mammalian cell is a p53 deficient cell. In other preferred embodiments, the mammalian cell is a tumor cell. Preferably, the cellular gene is a human gene, most preferably HFH-11, STEAP, RHAMM, INSIG1, LRPR1. Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.

In alternative embodiments, the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a cellular gene in Table 1. In these embodiments, inhibition of at least one of the cellular genes in Table 1 is assayed using the recombinant mammalian cell and decreased expression of the reporter gene detected in the presence and absence of the compound. In further preferred embodiments, the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound. Expression of reporter genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the reporter gene product.

In a third aspect, the invention provides compounds produced according to the methods of the invention, most preferably embodiments of the methods of the invention whereby the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound.

The invention in a fourth aspect provides a method for assessing efficacy of a treatment of a disease or condition relating to abnormal cell proliferation or neoplastic cell growth. The method comprises the steps of: obtaining a biological sample comprising cells from an animal having a disease or condition relating to abnormal cell proliferation or neoplastic cell growth before treatment and after treatment; comparing expression of at least one gene in Table 1, 2A or 2B after treatment with expression of

said genes before treatment; and determining that said treatment has efficacy for treating the disease or condition relating to abnormal cell proliferation or neoplastic cell growth if expression of at least one gene in Table 2A and 2B is higher after treatment than before treatment or expression of at least one gene in Table 1 is lower after treatment than before treatment. In preferred embodiments, the biological sample comprises tumor cells. Preferably, the gene is a cellular gene in Table 2A, most preferably wherein at least one cellular gene is a human gene that is BTG1, BTG2, EPLIN, WIP1, Maspin, MIC-1, IGFBP-6 or amphiregulin. In alternative preferred embodiments, the gene is a cellular gene in Table 1, most preferably a human gene that is HFH-11, STEAP, RHAMM, INSIG1, and LRPR1. Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.

In a fifth aspect, the invention provides a method for treating a disease or condition relating to abnormal cell proliferation or neoplastic cell growth, most preferably cancer. The method of the invention comprises the steps of administering to an animal having said disease or condition a therapeutically effective amount of a compound produced according to the inventive methods of the invention, most preferably embodiments of the methods of the invention whereby the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound.

In an additional aspect, the invention provides methods for detecting secreted proteins produced in senescent cells. In particular, the invention in this aspect provides diagnostic methods for determining, *inter alia*, whether a treatment that induces senescence in cells, preferably tumor cells, is effective. In preferred embodiments, detection assays as provided by the invention are performed on a bodily fluid, such as blood, urine, effusions, ascitic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, bronchial secretions, sputum, or secretions or washings from the breast. Preferred secreted proteins assayed in this aspect of the invention include maspin, MIC-1, IGFBP-6, and amphiregulin.

In a sixth aspect, the invention provides methods for identifying a compound that inhibits senescence-associated induction of cellular gene expression. In preferred embodiments of this aspect, the method comprises the steps of contacting the cell with a cytotoxic agent at a concentration of said agent that inhibits cell growth; assaying the cell  
5 in the presence and absence of the compound for changes in expression of cellular genes induced when cells become senescent; and identifying the compound as an inhibitor of senescence-associated induction of cellular gene expression if expression of the above cellular genes is induced in the absence of the compound but is not induced in the presence of the compound. In preferred embodiments, the cellular gene is a human gene  
10 that is cyclin D1, serum-inducible kinase, CYR61, prosaposin, transforming growth factor  $\alpha$  (TGF $\alpha$ ), kallikrein 7, calpain-L2, neurosin, plasminogen activator, urokinase, amyloid beta (A4) precursor protein ( $\beta$ APP), or integral membrane protein 2B (BRI/ITM2B). In a preferred embodiment, the mammalian cell is a p53 deficient cell. In other preferred embodiments, the mammalian cell is a tumor cell. Expression of cellular genes according  
15 to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.

In alternative embodiments, the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a human gene that is  
20 cyclin D1, serum-inducible kinase, CYR61, prosaposin, transforming growth factor  $\alpha$  (TGF $\alpha$ ), kallikrein 7, calpain-L2, neurosin, plasminogen activator, urokinase, amyloid beta (A4) precursor protein ( $\beta$ APP), or integral membrane protein 2B (BRI/ITM2B). In these embodiments, the method comprises the steps of contacting the mammalian cell with a cytotoxic agent at a concentration of said agent that inhibits cell growth; assaying  
25 the mammalian cell in the presence and absence of the test compound for expression of the reporter gene; and identifying compounds wherein expression of the reporter gene is not greater in the presence of the compound than in the absence of the compound. Expression of the reporter gene according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by  
30 assaying for an activity of the reporter gene product.

The invention also provides methods for monitoring the efficacy of treatment. In these embodiments, tumor cells that have become senescent and are no longer able to



grow are identified and distinguished from tumor cells that recover and proliferate after treatment. Senescence marker detection in biopsy samples from tumors obtained after patient treatment is used as an indicator of treatment response.

Specific preferred embodiments of the present invention will become evident from  
5 the following more detailed description of certain preferred embodiments and the claims.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a fluorescence-activated cell sorting (FACS) profile of proliferating and growth-arrested fractions of doxorubicin-treated HCT116 cells. Cells are sorted  
10 based on PKH2 fluorescence on the indicated days after release from doxorubicin. PKH2<sup>lo</sup> population of proliferating cells appears on day 4 and separates from the PKH2<sup>hi</sup> (growth-arrested) population by day 6.

Figure 1B is a FACS profile of proliferating and growth-arrested fractions of  
15 doxorubicin-treated HCT116 cells separated on the basis of DNA content. Exponentially growing HCT116 cells have a peak at G1, while the PKH2<sup>hi</sup> population isolated 9 days after drug treatment has a peak at G2/M.

Figure 1C is a photograph showing SA- $\beta$ -gal staining of PKH2<sup>hi</sup> and PKH2<sup>lo</sup>  
20 populations, separated 6 days after release from the drug. Both panels are photographed at the same 200x magnification.

Figure 1D is a photograph showing colony formation by PKH2<sup>hi</sup> and PKH2<sup>lo</sup>  
25 populations, separated 9 days after drug treatment and plated at 10,000 live (PI-negative) cells per 10-cm plate.

Figures 2A and 2B are photographs of RT-PCR analysis of changes in the expression of the indicated senescence-associated genes.  $\beta$ -actin was used as a normalization standard. Figure 2A shows a comparison of gene expression in  
30 proliferating (PKH2<sup>lo</sup>) and senescent (PKH2<sup>hi</sup>) populations of HCT116 cells, separated 9 days after doxorubicin treatment. Figure 2B is a comparison of gene expression in the

unsorted populations of wild-type, p21<sup>-/-</sup> and p53<sup>-/-</sup> HCT116 cells, before and after 24-hr treatment with 200 nM doxorubicin, and on the indicated days after release from the drug. Genes were designated as p53- or p21-dependent if changes in their expression became detectable at a later day or were less pronounced in the p53<sup>-/-</sup> or p21<sup>-/-</sup> lines than in the wild-type cells.

Figures 3A and 3B are photographs of immunoblotting analysis of changes in p53 and the indicated protein products of genes that show altered expression in drug-induced senescence.  $\beta$ -actin was used as a normalization standard. Figure 3A shows the results of immunoblotting of wild type HCT116 cells that were either untreated, treated for two days with 200 nM doxorubicin, or sorted into proliferating (PKH2<sup>lo</sup>) and senescent (PKH2<sup>hi</sup>) cell populations 9 days after doxorubicin treatment. Figure 3B shows the p53 dependence of p21 induction in doxorubicin-treated HCT116 cells, through immunoblotting analysis of the wild type, p21<sup>-/-</sup> and p53<sup>-/-</sup> HCT116 cell lines treated with doxorubicin for the indicated number of days.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

This invention provides genes the expression of which is modulated in cells that become senescent upon treatment with cytotoxic agents. The invention also provides methods for identifying compounds that mimic the gene expression modulating properties of cytotoxic agents but lack toxicity that is characteristic of chemotherapeutic drug treatment, as well as the compounds identified by the methods. Diagnostic and therapeutic treatment methods are provided as set forth more particularly herein.

For the purposes of this invention, the term "senescence" will be understood to include permanent cessation of DNA replication and cell growth not reversible by growth factors, such as occurs at the end of the proliferative lifespan of normal cells or in normal or tumor cells in response to cytotoxic drugs, DNA damage or other cellular insult. Senescence is also characterized by certain morphological features, including increased size, flattened morphology increased granularity, and senescence-associated  $\beta$ -galactosidase activity (SA- $\beta$ -gal).

As used herein, the term "senescence-associated gene" is intended to encompass genes the expression of which is modulated (either induced or repressed) when a cell expresses a senescent phenotype, particularly a senescence phenotype produced by contacting the cells with a cytotoxic agent. Most preferably, the term will be understood to refer to the genes disclosed herein, *inter alia*, in Tables 1 and 2.

Senescence can be conveniently induced in mammalian cells by contacting the cells with a dose of a cytotoxic agent that inhibits cell growth (as disclosed in Chang *et al.*, 1999a, *ibid.*). Cell growth is determined by comparing the number of cells cultured in the presence and absence of the agent and detecting growth inhibition when there are fewer cells in the presence of the agent than in the absence of the agent after an equivalent culture period of time. Examples of such cytotoxic agents include but are not limited to doxorubicin, aphidicolin, cisplatin, cytarabine, etoposide, taxol and ionizing radiation. Appropriate dosages will vary with different cell types; the determination of the dose that induces senescence is within the skill of one having ordinary skill in the art, as disclosed in Chang *et al.*, 1999a, *ibid.*

For the purposes of this invention, reference to "a cell" or "cells" is intended to be equivalent, and particularly encompasses *in vitro* cultures of mammalian cells grown and maintained as known in the art, as well as biological samples obtained, *inter alia*, from tumor specimens *in vivo*.

For the purposes of this invention, reference to "cellular genes" in the plural is intended to encompass a single gene as well as two or more genes. It will also be understood by those with skill in the art that effects of modulation of cellular gene expression, or reporter constructs under the transcriptional control of promoters derived from cellular genes, can be detected in a first gene and then the effect replicated by testing a second or any number of additional genes or reporter gene constructs. Alternatively, expression of two or more genes or reporter gene constructs can be assayed simultaneously within the scope of this invention.

The methods of the invention can be practiced using any mammalian cell, preferably a rodent or primate cell, most preferably a human cell that can develop a senescence phenotype in response to a cytotoxic agent. Preferred cells include mammalian cells, preferably rodent or primate cells, and most preferably human cells. In certain embodiments, most preferred cells are p53 deficient cells, that are cells expressing

less than the normal amount or less than the normal functional activity of tumor suppressor p53 as the result of mutation, deletion, recombination, chromosome loss or genetic manipulation.

In certain embodiments, the methods of the invention are advantageously practiced using recombinant mammalian cells comprising a recombinant expression construct encoding a reporter gene operably linked to a promoter from a gene that is induced in senescent cells. Preferred reporter genes comprising said constructs include firefly luciferase, chloramphenicol acetyltransferase, beta-galactosidase, green fluorescent protein (GFP), alkaline phosphatase and most particularly a commercially-available GFP-luciferase fusion gene. Most preferred promoters comprising the recombinant expression constructs of the invention are promoters from a cellular gene known to be induced in senescent cells. The cellular gene promoter is advantageously from a gene identified in Table 2A herein. In more preferred embodiments, the cellular promoter is from BTG1, BTG2, EPLIN, WIP1, Maspin, MIC-1, IGFBP-6 or amphiregulin. In alternative embodiments, the cellular gene promoter is from a gene that is repressed in senescent cells. Preferred promoters of this type include promoters from a gene identified in Table 1 herein. In more preferred embodiments, the cellular promoter is from HFH-11, STEAP, RHAMM, INSIG1, LRPR1.

Promoter sequences from some of these genes are known in the art. These include: cyclin D1 (Motokura & Arnold, 1993, *Genes Chromosomes Cancer* 7: 89-95); CYR61 (Latinkic *et al.*, 1991, *Nucleic Acids Res.* 19: 3261-7); prosaposin (Sun *et al.*, 1998, *Gene* 218: 23-34); transforming growth factor  $\alpha$  (TGF $\alpha$ ; Raja *et al.*, 1991, *Mol. Endocrinol.* 5: 514-20); kallikrein 7 (Yousef *et al.*, 2000, *Gene* 254: 119-128); calpain-L2 (Suzuki *et al.*, 1995, *Biol Chem Hoppe Seyler.* 376: 523-9); plasminogen activator urokinase (Riccio *et al.*, 1985, *Nucleic Acids Res.* 13: 2759-71); and amyloid beta (A4) precursor protein ( $\beta$ APP; Lahiri & Robakis, 1991, *Brain Res. Molec. Brain Res.* 9: 253-257).

For other genes, promoter sequences can be readily isolated from a region of genomic DNA within about 5 kilobases (and more typically within 1 kilobase) upstream of a cDNA encoding the gene. The availability of the complete sequence of the human genome permits the genomic region 5' to any gene to be inspected for consensus promoter sequences, such as AT-rich sequences termed "TATA" boxes, and additional

sequences comprising the sequence "CAAT" that are recognized as mediating the interaction of the nucleic acid of the promoter with protein factors such as RNA polymerase. Putative promoters can be readily tested by inserting the putative promoter sequence upstream from a reporter gene and comparing reporter gene activity in such constructs with activity in constructs without the putative promoter insert.

Recombinant expression constructs can be introduced into appropriate mammalian cells as understood by those with skill in the art, most preferably transfection and electroporation. Preferred embodiments of said constructs are produced in plasmid vectors or other vectors that can be used to easily produce useful quantities of the vector. Alternative embodiments include transmissible vectors, more preferably viral vectors and most preferably retrovirus vectors, adenovirus vectors, adeno-associated virus vectors, and vaccinia virus vectors, as known in the art. See, generally, MAMMALIAN CELL BIOTECHNOLOGY: A PRACTICAL APPROACH, (Butler, ed.), Oxford University Press: New York, 1991, pp. 57-84. Cells transiently transfected with the recombinant expression construct and more preferably cells stably transfected with the construct and selected using a selective agent are advantageously used in the practice of certain embodiments of the methods of the invention.

Detection of the senescence response in clinical cancers requires diagnostic markers for senescent cells. The most common senescence marker, SA- $\beta$ -gal (Dimri *et al.*, 1995, *Proc. Natl. Acad. Sci. USA* 92: 9363-9367), has two major disadvantages: it represents an enzymatic activity which is preserved only in frozen tissue samples and for a limited period of time, and it is not mechanistically related to growth arrest of senescent cells. The invention provides a number of genes that are upregulated in senescent cells. These proteins provide sensitive diagnostic markers for cytotoxic agent-induced senescence. Of special interest as diagnostic markers are several genes that are upregulated in senescent cells and are functionally related to growth arrest, such as EPLIN, BTG1, BTG2, WIP1, Maspin, MIC-1, IGFBP-6 and amphiregulin. Induction of these senescence-associated growth inhibitors is not limited to doxorubicin-treated HCT116 cells; for example EPLIN, a growth-inhibitory protein that was downregulated in 20 of 21 carcinoma cell lines relative to normal epithelial tissues (Maul *et al.*, 1999, *Oncogene* 18: 7838-7841), is strongly induced in MCF-7 breast carcinoma cells by treatment with retinoids, under the conditions that produce senescence-like growth arrest

(Dokmanovic *et al.*, 2002, *Cancer Biol. Ther.* 1: 16-19 and in co-owned and co-pending U.S. Serial No. 09/865,879, filed May 25, 2001, incorporated by reference herein). Retinoid treatment was also shown to induce a secreted growth inhibitor IGFBP-6 (Dailly *et al.*, 2001, *Biochim. Biophys. Acta* 1518: 145-151). Most of the other senescence-associated growth inhibitors have been shown to be induced by DNA damage in a variety of other tumor-derived cell lines, including BTG1 (Cortes *et al.*, 2000, *Mol. Carcinogen.* 27: 57-64), BTG2 (Fletcher *et al.*, 1991, *J. Biol. Chem.* 266: 14511-14518), WIP1 (Fiscella *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 6048-6053), Maspin (Zou *et al.*, 2000, *J. Biol. Chem.* 275: 6051-6054 and MIC-1 (Komarova *et al.*, *ibid.*). However, none of these studies appreciated the association of these genes with senescence, and the general inducibility of such genes by DNA damage disclosed herein strongly indicates that such genes are broadly applicable markers of damage-induced senescence.

The invention also provides genes the expression of which is downregulated in cytotoxic agent-induced senescence. These genes are useful for detecting senescence in tumor cells in like manner as genes that are induced during senescence, except that senescence will be marked by downregulation of such genes. Several of these genes are of special interest as markers that are downregulated in senescent cells, including HFH-11 (Trident), a transcription factor implicated in cell cycle progression (Ye *et al.*, 1999, *Mol. Cell. Biol.* 19: 8570-8580), STEAP, a gene overexpressed in different cancers (Hubert *et al.*, 1999, *Proc. Natl. Acad. Sci. USA* 96: 14523-14528), RHAMM, shown to have oncogenic activity (Hall *et al.*, 1995, *Cell* 82: 19-26) INSIG1, implicated in liver regeneration (Peng *et al.*, 1997, *Genomics* 43: 278-284) and LRPR1 that mediates proliferative response to FSH (Slegtenhorst-Eegdeeman *et al.*, 1995, *Mol. Cell. Endocrinol.* 108: 115-24).

Changes in gene expression, either induction or repression and either native genes of reporter gene constructs as disclosed herein, are detected using methods well-established in the art. These include hybridization assays for detecting cellular nucleic acid, most preferably mRNA, said assays including northern hybridization, Southern hybridization, and any of a variety of *in vitro* amplification methods known in the art. Gene expression changes can also be detected using immunological reagents and methods, including enzyme-linked immunosorbent assay (ELISA) and other assays using polyclonal or monoclonal antibodies, antibody fragments or recombinant or chimeric

antibodies and such immunological reagents. Activity of specific gene products, most preferably used with reporter gene constructs having known and quantifiable activities and most preferably producing easily-detected products are also advantageous for detecting senescence-associated changes in gene expression.

5 Elucidation of molecular changes associated with treatment-induced senescence is also advantageous therapeutically. Permanently arresting tumor cell growth through the induction of accelerated senescence is an attractive treatment approach, since this response to drug treatment can be elicited even under the conditions of minimal cytotoxicity. The instant disclosure that drug-induced senescence is associated with  
10 concerted induction of multiple antiproliferative genes (some of which also inhibit the growth of neighboring cells) suggests the existence of common regulatory pathways activating such genes. Importantly, most of the growth-inhibitory genes are also induced by doxorubicin treatment in p53-deficient cells. Agents that can be developed to stimulate the induction of senescence-associated growth-inhibitory genes are likely therefore to be  
15 efficacious against tumors with or without functional p53.

The obverse side of drug-induced senescence, however, is the induction of genes associated with pathological conditions (such as Alzheimer's disease), as well as proteases and mitogenic, antiapoptotic and angiogenic secreted factors. Expression of such genes by senescent cells may have potentially adverse effects in the short term  
20 (growth stimulation of non-senescent tumor cells) and in the long term (increased likelihood of de novo carcinogenesis and age-related diseases). A linkage between cell senescence and carcinogenesis in vivo has been suggested by a recent study of Paradis *et al.* (2001, *Human Pathol.* 32: 327-332), who found that SA- $\beta$ -gal expression in normal human liver was strongly correlated with the development of hepatocellular carcinoma.  
25 Such linkage was also directly demonstrated by Krtolica *et al.* (2001, *Proc. Natl. Acad. Sci. USA* 98: 12072-12077), who found that mixing transformed epithelial cells with senescent (but not with pre-senescent) fibroblasts enhances the growth and tumorigenicity of the transformed cells. p21 induction upregulates many disease-associated genes and induces paracrine anti-apoptotic and mitogenic activities (Chang *et al.*, 2000, *ibid.*), and  
30 p21 knockout was shown herein to decrease or delay the induction of such genes as prosaposin, TGF $\alpha$  and Alzheimer's  $\beta$ APP. These observations suggest that p21-

stimulated regulatory pathways may be largely responsible for the expression of disease-associated genes in senescent cells.

The present invention provides methods for identifying compounds that induce senescence in tumor cells without concomitantly inducing expression of said mitogenic, antiapoptotic and angiogenic secreted factors or genes associated with pathological conditions. The existence of such compounds is suggested by the behavior of retinoids, which induce tumor cell senescence through co-activation of several growth-inhibitory genes but not of p21 or other genes associated with pathological conditions (as disclosed in co-owned and co-pending U.S. Serial No. 09/865,879, filed May 25, 2001, incorporated by reference herein and in Dokmanovic *et al.*, 2002, *Cancer Biol. Ther.* 1: 16-19), and the present invention provides methods to identify other compounds dissociated from cytotoxicity or other confounding features of compounds known in the art to produce senescence in tumor cells.

The invention also provides methods for monitoring the efficacy of treatment, by identifying tumor cells that have become senescent and are no longer able to grow and distinguishing said cells from tumor cells that recover and proliferate after treatment. The detection of the markers of senescence in the biopsies of treated tumors can be used as an indicator of treatment response. This type of diagnostics should be useful in many clinical situations, including for example as a biopsy test to evaluate the success of radiation therapy that may potentially require several months or even years for complete response (see Cox *et al.*, 1983, *Int. J. Radiat. Oncol. Biol. Phys.* 9: 299-303; Bataini *et al.*, 1988, *Am. J. Surg.* 155: 754-760). The predominance of tumor cells that express markers of senescence is expected to be positively correlated with the success of treatment. Expression of the corresponding genes can be measured at the protein level, using antibodies against the corresponding gene products for *in situ* immunostaining, enzyme-linked immunosorbent assay (ELISA), or western blotting. Gene expression can also be measured at the nucleic acid level, most preferably by detecting expression of RNA encoding at least one of said genes, using *in situ* hybridization, *in situ* RT-PCR, or bulk RNA analysis techniques, such as RT-PCR or different forms of filter hybridization (including northern blotting). The choice of markers that are inhibited in senescent cells is provided by the genes listed in Table 1. The choice of senescence markers that are induced in senescent cells is provided by the genes listed in Table 2. Markers inhibited in



senescent cells include the genes that are causally involved in cell proliferation and are known to be inhibited in other systems of cell senescence, including for example Ki-67 (which is already widely used as a proliferation marker), CENP-F, AIM-1, MAD-2, ribonucleotide reductase M1, and thymidine kinase. Such markers also include genes that show tumor-specific expression and have not been previously shown to be inhibited in senescence, such as STEAP, RHAMM or TLS/FUS. Of special interest as senescence markers are the genes that are induced in senescent cells and are causally involved in cell growth inhibition, including for example BTG1, BTG2, EPLIN, WIP1, Maspin, MIC-1, IGFBP-6 or amphiregulin, and other genes expression of which is downregulated in tumors relative to normal tissues, such as P-cadherin, desmoplakin, desmoyokin, and neurosin.

Some of the genes that are induced in senescent cells encode secreted proteins that can be detected not only within the affected tissues but also in bodily fluids, such as blood, urine, effusions, ascitic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, bronchial secretions, sputum, or secretions or washings from the breast. Four of these secreted proteins (maspin, MIC-1, IGFBP-6, amphiregulin) act as tumor growth inhibitors, and their induction by cancer therapeutic agents should contribute to the success of therapy. The levels of such proteins in the blood or urine of patients, measured after the administration of chemotherapy or a course of radiation, are expected therefore to provide a diagnostic parameter that will correlate with the probability of treatment success. Maspin (Zou *et al.*, 2000, *J. Biol. Chem.* 275: 6051-6054) and MIC-1 (Komarova *et al.*, 1998, *Oncogene* 17: 1089-1096) have been previously reported to be induced by chemotherapeutic agents or radiation, whereas IGFBP-6 is known to be inducible by retinoids (Dailly *et al.*, 2001, *Biochim. Biophys. Acta* 1518: 145-151) and amphiregulin is induced by vitamin D (Akutsu *et al.*, 2001, *Biochem. Biophys. Res. Commun.* 281: 1051-1056), but stable induction of these proteins in cells undergoing treatment-induced senescence was not known in the prior art.

Antibodies against the above proteins have been developed and many of them are available commercially. For example, anti-Maspin antibody is available from PharMingen, San Diego, CA (Catalog # 554292), anti-amphiregulin antibody is available from Lab Vision Corp., Fremont, CA (Catalog # RB-257-P), and anti-IGFBP-6 antibody

is available from Cell Sciences, Inc., Norwood, MA (Catalog # PAU1). Monoclonal antibodies against MIC-1 have been described in the art (Fairlie *et al.*, 2001, *Biochemistry* 40: 65-73). These or similar antibodies can be used most conveniently in an ELISA assay, or in other conventional immunochemical assays, to detect and measure the amount of corresponding proteins. Although protein levels in blood or urine that correlate with treatment success are not presently known, they can be determined through straightforward clinical studies. In such studies, the corresponding protein levels are measured in patients before treatment and at different time points after the administration of treatment. The results of these measurements are then correlated with standard clinical criteria for treatment success (partial remission and subsequently complete remission).

As disclosed herein, cytotoxic agent-inducible and repressible genes are useful targets for identifying compounds other than cytotoxic agents that mimic the physiologically-based growth inhibitory effect on cell proliferation. Identifying such compounds advantageously provides alternative agents for producing growth arrest in mammalian cells, particularly tumor cells and other cells that proliferate inappropriately or pathogenically. Such compounds are beneficial because they can mimic the growth-inhibitory effects of cytotoxic agents.

Another advantage of such compounds is that they can be expected to have a growth-inhibitory effect without producing systemic side effects found with other growth-inhibitory compounds known in the prior art. For example, many growth-inhibitory drugs and compounds known in the prior art disadvantageously induce p21 gene expression, which induces senescence, growth arrest and apoptosis by activating a plurality of genes, the expression of which is associated with the development of diseases, particularly age-related diseases such as Alzheimer's disease, atherosclerosis, renal disease, and arthritis (as disclosed in co-owned and co-pending U.S. Serial No. 60/265,840, filed February 1, 2001 (Attorney Docket No. 99,216-E) and U.S. Serial No. 09/861,925, filed May 21, 2001 (Attorney Docket No. 99,216-F), incorporated by reference herein). Discovery of compounds that mimic the growth-inhibitory effects of cytotoxic agents chemotherapeutic drugs without producing the toxic side effects of growth-inhibitory compounds known in the art is advantageously provided by the invention.

Identification herein of cytotoxic agent-induced senescence-associated genes with pathogenic activity provides targets for developing drugs that inhibit the induction of such

genes. The invention provides methods for assaying test compounds that inhibit induction of senescence-associated genes consequent to cytotoxic agent-induced senescence, by contacting cells with the test compound. Compounds that inhibit induction of these genes show no increased expression of these genes in agent-treated cells compared with untreated cells. Reporter gene constructs are also advantageously used to assay gene induction and lack thereof in the methods of the invention directed to these disease-associated genes.

The following Examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature.

### EXAMPLE 1

#### **Permanent Growth Arrest in Tumor Cells Treated with a Cytotoxic Agent is Associated With the Development of a Senescent Phenotype**

Cytological and gene expression analyses were performed to determine the effects of doxorubicin, a widely used anticancer drug that produces DNA damage by stabilizing a cleavable intermediate complex formed by topoisomerase II in the process of DNA segregation, on human colon cancer cells (HCT 116) in culture.

HCT116 colon carcinoma cells (Myohanen *et al.*, 1998, *Cancer Res.* 58: 591-593; Accession No. CCL-247, American Type Culture Collection, Manassas, VA), including wild-type, p21<sup>-/-</sup> (clone 80S4) and p53<sup>-/-</sup> (clone 379.2) cell lines (a gift of Dr. B. Vogelstein, Johns Hopkins University) were grown in Dulbecco Modified Eagle Medium with 10% FC2 serum. Cells were plated at  $5 \times 10^6$  cells per 15-cm plate and treated for 24-hr with 200 nM doxorubicin. Thereafter, cells were allowed to recover in drug-free media up to 10 days. For fluorescence-activated cell sorter (FACS) analysis of cell division, cells were labeled with PKH2 (a lipophilic fluorophore; Sigma Chemical Co., St. Louis, MO), which stably incorporates into the plasma membrane and distributes evenly between daughter cells, resulting in gradual decrease in PKH2 fluorescence during consequent cell divisions (Horan *et al.*, 1989, *Nature* 340: 167-168). FACS analysis and cell sorting carried out as described in Chang *et al.* (1999, *Cancer Res.* 59: 3761-3767 and 1999, *Oncogene* 18: 4808-4818). Sorted fractions of senescent (PKH2<sup>hi</sup>) and proliferating (PKH2<sup>lo</sup>) cells (90-95% purity) were analyzed for DNA content using

propidium iodide (PI) staining and FACS analysis as described by Jordan *et al.* (1996, *Cancer Res.* 56: 816-825). The cells were also stained for senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -gal) activity as described by Dimri *et al.* (1995, *Proc. Natl. Acad. Sci. USA* 92: 9363-9367). Finally, clonogenicity of the sorted populations was tested by  
5 plating 2,000-10,000 sorted cells per 10-cm plate.

The results of these assays are shown in Figures 1A through 1D. Cell proliferation as detected by FACS using PKH2 fluorescence is shown in Figure 1A. Changes in PKH2 fluorescence were monitored by FACS on different days after doxorubicin treatment. Cells that died after drug treatment were excluded from this  
10 analysis based on their staining with membrane-impermeable dye PI. Almost all PI-negative cells remained growth-arrested (PKH2<sup>hi</sup>) for the first 2-3 days after doxorubicin treatment, but a proliferating cell population (PKH2<sup>lo</sup>) emerged starting from day 4. A substantial fraction of cells, however, remained PKH2<sup>hi</sup> and did not decrease their fluorescence, indicating that these cells did not divide even once after release from the  
15 drug. 6-10 days after doxorubicin treatment, the surviving cells were separated by FACS into PKH2<sup>hi</sup> and PKH2<sup>lo</sup> fractions.

DNA content analysis showed that most of PKH2<sup>hi</sup> cells remained in G2, the phase where most of the cells had been originally arrested by doxorubicin through its effect on topoisomerase II (Figure 1B). As shown in Figure 1C, PKH2<sup>hi</sup> cells were  
20 greatly enlarged and stained positively for SA- $\beta$ -gal, indicating their senescent phenotype. In contrast, PKH2<sup>lo</sup> cells retained normal size and remained negative for SA- $\beta$ -gal. The ability to form colonies was essentially confined to the PKH2<sup>lo</sup> fraction (Figure 1D), indicating that the senescent PKH2<sup>hi</sup> cells have lost their proliferative capacity.

25 These results clearly indicated that HCT 116 cells were separated into two different populations following doxorubicin treatment: a senescent cell population and a population that regained the capacity to proliferate.

30

## EXAMPLE 2

### Identification of Genes Induced and Repressed in Doxorubicin-Induced Senescence

The populations of senescent and proliferating cells produced by doxorubicin treatment of HCT 116 cells as described in Example 1 were used to identify differences in gene expression between these cell populations and untreated cells.

In these experiments, poly(A)<sup>+</sup> RNA and protein extracts were prepared from  
5 PKH2<sup>lo</sup> and PKH2<sup>hi</sup> cell populations, separated in different experiments 6, 9 or 10 days after release from doxorubicin. Fluorescent cDNA probes were synthesized and used for hybridization with the Human UniGEM V 2.0 cDNA microarray and signal analysis (assays were conducted by IncyteGenomics, St. Louis, MO, as described at that company's web site, [www.incyte.com](http://www.incyte.com)). Changes in gene expression were verified by  
10 semi-quantitative reverse transcription-PCR (RT-PCR), essentially as described (Noonan *et al.*, 1990, *Proc. Natl. Acad. Sci. USA* 87: 7160-7164), using  $\beta$ -actin as an internal normalization standard and the oligonucleotide primers shown in Table 3. RT-PCR analysis was carried out using two pairs of proliferating- and senescent-cell RNA preparations isolated in independent experiments, with the same results; for a subset of  
15 the genes, the assays were reproduced with the same pair of RNA samples. These results were confirmed by immunoblotting assays that were carried out at least twice (with the same results), using the following primary antibodies: mouse monoclonal antibodies against  $\beta$ -actin (Sigma Chemical Co.), p53 and p21 (Oncogene Research, Cambridge, MA), Maspin (Pharmingen, San Diego, CA), keratin 18 (Neomarkers, Union City, CA),  
20 cyclin D1 (Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit polyclonal antibodies against ATF-3 (Santa Cruz), Mad-2 (BabCo, Richmond, CA) and EPLIN (a gift of Dr. D. Chang, UCLA). Bands were detected using horseradish peroxidase-labeled secondary antibodies and ECL chemiluminescence detection kit (Amersham Pharmacia Biotech, Piscataway, NJ).

25 Fluorescent cDNA probes were prepared from RNA of senescent (PKH2<sup>hi</sup>) and proliferating (PKH2<sup>lo</sup>) cell populations and used for differential hybridization with UniGEM V 2.0 human cDNA microarray (IncyteGenomics, Inc.), containing >9,000 genes. 82% of the more than 9,000 sequence-verified genes and expressed sequence tags (ESTs) present in the UniGem V 2.0 microarray gave measurable hybridization signals  
30 with both probes. Lists of genes identified by this hybridization as downregulated or upregulated in the senescent relative to proliferating cells (with balanced differential expression of 2.0 or higher) are provided in Tables 1 and 2.

RT-PCR analysis (Figure 2A) was carried out for 74 individual genes detected using the hybridization assay and confirmed qualitative changes in gene expression for 26/29 downregulated and 37/45 upregulated genes. In most cases, differences in gene expression revealed by RT-PCR were much higher than the values indicated by cDNA  
5 microarray hybridization. Changes in the expression of 7 genes were also confirmed at the protein level by immunoblotting (Figure 3A).

More than one half of 68 genes and ESTs downregulated in senescent cells are known to play a role in cell cycle progression: 25 of these genes are involved in different stages of mitosis or DNA segregation (*e.g.*, CDC2, Ki-67, MAD2, Topoisomerase II $\alpha$ );  
10 11 genes function in DNA replication and chromatin assembly (*e.g.* ribonucleotide reductase M1, thymidylate kinase, replication protein A3); and 4 genes are involved in DNA repair (*e.g.* HEX1, FEN1). Downregulation of genes involved in cell proliferation correlates with the growth-arrested state of senescent cells and demonstrates the biological relevance of gene expression profiling in our system.

15 In addition, multiple growth-inhibitory genes were induced by doxorubicin treatment. Senescent HCT116 cells were found to upregulate multiple genes with documented growth-inhibitory activity, providing an ample explanation for the maintenance of doxorubicin-induced cell cycle arrest in the absence of p16 (which is not expressed in HCT 116 cells). One of the upregulated genes is p21 (shown in Figure 2A).  
20 Analysis of p21 and p53 protein induction by doxorubicin in wild type, p53<sup>-/-</sup> (14) and p21<sup>-/-</sup> (15) HCT116 cell lines demonstrated that p21 induction in this system is strongly dependent on p53 (shown in Figure 3B). Both p53 and p21 proteins are maintained at elevated levels in senescent cells isolated 9 days after release from the drug (Figure 3A). In contrast to p21, however, p53 is upregulated only at the protein level.

25 In addition to sustained p21 induction, senescent cells strongly overexpress many other growth inhibitors, including several known or putative tumor suppressor genes. Some of these genes encode intracellular growth-inhibitory proteins, including tumor suppressor BTG1 and its homolog BTG2, putative tumor suppressor EPLIN (Epithelial Protein Lost in Neoplasm) and WIP1 phosphatase. Senescent HCT116 cells also  
30 overexpress several secreted growth inhibitors, including MIC-1 (pTGF- $\beta$ ), insulin-like growth factor binding protein-6 (IGFBP-6), serine protease inhibitor Maspin (a tumor suppressor downregulated in advanced breast cancers), and amphiregulin, an EGF-related

factor that inhibits proliferation of several carcinoma cell lines while promoting the growth of normal epithelial cells. These findings suggest that drug-induced growth arrest of tumor cells is maintained by a set of apparently redundant intracellular and paracrine factors.

5 Differences in gene expression between senescent and proliferating populations of drug-treated HCT116 cells parallel the differences between normal and cancerous epithelial cells. In addition to the above listed tumor suppressors, senescent HCT116 cells induce several other genes that are downregulated in cancers relative to normal epithelial cells (including MIC-1, P-cadherin, desmoplakin, desmoyokin, neurosin). On  
10 the other hand, senescent cells downregulate not only multiple genes involved in cell proliferation but also some other genes that have oncogenic activity (RHAMM and TLS/FUS) or show tumor-specific expression (STEAP). Another sign of putative “normalization” of senescent cells is the upregulation of six members of the keratin gene family. The strongest induction in this group was observed for keratins 8 and 18, a keratin  
15 pair with anti-apoptotic activity (Caulin *et al.*, 2000, *J. Cell Biol.* 149: 17-22). However, senescent HCT116 cells show no evidence of apoptosis, even though they upregulate two proapoptotic genes, APO-1/Fas and NOXA.

In addition to the growth-inhibitory genes, senescent HCT116 cells show increased expression of genes for secreted mitogenic, anti-apoptotic and angiogenic  
20 factors, such as extracellular matrix (ECM) proteins Cyr61 and prosaposin, and transforming growth factor  $\alpha$  (TGF- $\alpha$ ). Induction of such genes results in paracrine activities, which promote tumor cell growth *in vitro* and *in vivo*. Such activities have been previously associated with replicative senescence (Campisi, 2000, *In vitro* 14: 183-188) in normal cells, and with p21 induction in tumor cells (Chang *et al.*, 2000, *Proc.*  
25 *Natl. Acad. Sci. USA* 97: 1497-150117). Senescent HCT 116 cells also upregulate several proteases (kallikrein-7, calpain L2, neurosin, urokinase-type plasminogen activator) that may potentially contribute to metastatic growth. Several other genes induced in senescent HCT 116 cells are involved in cell adhesion and cell-cell contact (including P-cadherin, Mac2-binding protein and desmoplakin). Other induced genes encode ECM receptors,  
30 including several integrins and syndecan-4 (ryudocan), involved in angiogenesis. Some other transmembrane proteins induced in senescent cells are growth-regulatory proteins CD44 and Jagged-1, Alzheimer’s  $\beta$ -amyloid precursor protein ( $\beta$ APP), and another

amyloid precursor, BRI, associated with an Alzheimer-like disease. Altogether, secreted factors, ECM proteins, ECM receptors and other integral membrane proteins make up 33 of 68 genes with known functions that are induced in senescent HCT116 cells. In contrast, only 2 of 64 downregulated genes with known function were induced in the  
5 senescent cell population of HCT 116 cells treated with doxorubicin.

One class of genes that are differentially expressed in doxorubicin-treated HCT 116 cells are genes encoding known or putative transcription factors or cofactors. Genes for several known or putative transcription factors and cofactors show altered regulation in the senescent HCT116 cells. One of the downregulated transcription factors is winged  
10 helix protein HFH-11 (Trident), a positive regulator of DNA replication, that is specifically expressed in cycling cells (Ye *et al.*, 1999, *Mol. Cell. Biol.* 19: 8570-8580). Several upregulated transcription factors are related to the AP-1 family, which mediates cellular responses to various mitogenic signals, interferons and different forms of stress (Wisdom, 1999, *Exp. Cell. Res.* 253: 180-185). These include c-Jun and two other basic  
15 leucine zipper proteins, XBP-1 (structurally related to c-Jun) and ATF3 that dimerizes with c-Jun. Sustained upregulation of ATF3 mRNA and protein in senescent cells is surprising, since induction of this stress-responsive factor is usually transient (over hours), due to the ability of ATF3 to inhibit its own transcription (Wolfgang *et al.*, 2000, *J. Biol Chem.* 275: 16865-16870). Another induced transcription factor is ELF-1, a  
20 member of Ets family of helix-loop-helix proteins that are known to interact functionally, and possibly physically, with AP-1 (Wisdom, *ibid.*).

The observed pattern of gene expression in cytotoxic drug-induced senescence of HCT116 cells showed many similarities to senescence in normal cells. Some of the general properties of senescent cells (other than terminal growth arrest) are resistance to  
25 apoptosis, increased cell adhesion (associated with overproduction of ECM components), and secretion of proteases, protease inhibitors, and mitogenic factors (Campisi, *ibid.*). Genes involved in all of these phenomena are amply represented among those that are upregulated in senescent HCT 116 tumor cells. In contrast to normal cells, however, senescent HCT116 cells don't upregulate p16 or tumor suppressor PML associated with  
30 RAS-induced accelerated senescence (Pearson *et al.*, 2000, *Nature* 406: 207-210).

Changes in gene expression associated with drug-induced senescence also show parallels with organism aging. Some of the proteins that are induced in the senescent



HCT116 colon carcinoma cells, such as  $\beta$ APP and prosaposin, show age-dependent expression in animals. Remarkably, Maspin, CD44 and Cyclin D1 were reported to be upregulated specifically in the colonic epithelium of aging animals (Lee *et al.*, 2001, *Mech Ageing Dev.* 122: 355-371). In addition, eight genes downregulated in senescent  
5 HCT116 cells also showed decreased expression in actively growing fibroblast cultures from old people relative to similar cultures from young people, whereas two induced genes (MIC-1 and desmoplakin) were upregulated in cultures from older individuals (Ly *et al.*, 2000, *Science* 287: 2486-2492). These results demonstrate that the process of drug-induced senescence in tumor cells is related to both replicative senescence and organism  
10 aging.

### EXAMPLE 3

#### **Effects of p53 and p21 Knockout on Cytotoxic Drug-induced Changes in Senescence-associated Gene Expression**

15 Many of the genes that show altered expression in senescent HCT116 cells have shown similar changes upon overexpression of p53 (9 downregulated and 11 upregulated genes) or p21 (46 downregulated and 7 upregulated genes) (see Tables 1 and 2). p53 acts as a direct transcriptional activator of many genes (including p21) and indirectly regulates a group of genes that do not have p53-binding sites in their promoters (Komarova *et al.*,  
20 1998, *Oncogene* 17: 1089-1096; Zhao *et al.*, 1999, *Cell Res.* 9: 51-59). A prominent class of p53-induced genes encode secreted growth-inhibitory factors, providing paracrine antiproliferative activity (Komarova *et al.*, *ibid.*). In contrast to p53, p21 is not a transcriptional regulator *per se*, but it interacts with a broad network of transcription factors, cofactors and mediators of signal transduction (Dotto, 2000, *Biochim. Biophys.*  
25 *Acta* 1471: M43-M56). Overexpression of p21 in fibrosarcoma cells results in downregulation of multiple cell proliferation genes and upregulation of many ECM components and secreted mitogenic and antiapoptotic factors, providing the corresponding activities in conditioned media of p21-induced cells (Chang *et al.*, 2000, *ibid.*). A known mechanism for transcription activation by p21 is based on its ability to  
30 stimulate p300/CBP transcription cofactors (Snowden *et al.*, 2000, *Mol. Cell. Biol.* 20: 2676-2686). HCT116 cells, however, express a dominant mutant form of transcription

factor p300 (Gayther *et al.*, 2000, *Nat. Genet.* 24: 300-303), which may explain why senescent HCT116 cells upregulate a relatively small number of p21-inducible genes.

To elucidate the roles of p53 and p21 in the observed changes in gene expression, expression of senescence-associated genes upon doxorubicin treatment of wild type, p21-  
5   /- and p53-/- HCT116 cells was analyzed. RNA samples were isolated before the addition of the drug, immediately after one-day treatment with doxorubicin, and on three consecutive days after the removal of the drug. Expression of 33 genes that were upregulated and 11 genes downregulated in senescent cells was analyzed by RT-PCR as described above; results are shown in Figure 2B.

10       This analysis showed that all the tested genes were expressed in the untreated wild-type cells at levels similar to those in the proliferating fraction of doxorubicin-treated cells. Senescence-associated changes in the expression of most of these genes became detectable in the total population of wild-type HCT116 cells after one-day doxorubicin treatment or one day after release from the drug. This early response made it  
15   possible to evaluate the effects of p21 and p53 knockouts on total populations of doxorubicin-treated cells, without having to purify the small senescent fractions of p21-/- and p53-/- cell lines.

Approximately one third of the genes that are upregulated in senescent cells showed almost indistinguishable response among the wild-type, p21-/- and p53-/- cell  
20   lines, indicating that the induction of these genes does not involve either p53 or p21 (Figure 2B). These genes include tumor suppressor BTG1 and secreted growth inhibitor IGFBP-6. Surprisingly, one of the genes that shows no p53 dependence is NOXA, although it is known to be inducible by p53. The remaining two thirds of the upregulated genes showed diminished or delayed induction in p53-/- cells. About one half of the  
25   latter genes were unaffected by p21 knockout. This group includes transcription factors of the AP-1 family, CYR61, and several intracellular (BTG2, WIP1) and secreted growth inhibitors (Maspin, MIC-1, amphiregulin). None of these genes, however, are completely dependent on p53 for their induction, and all of them are induced in p53-/- cells two days after release from the drug. Almost all senescence-associated growth inhibitors (except  
30   for p21 and EPLIN) are eventually induced in p53-/- cells to a level comparable to the wild-type cell line (Figure 2B). These results provide an explanation for the diminished

but still substantial induction of senescence-like growth arrest in p53<sup>-/-</sup> cells after doxorubicin treatment (Chang *et al.*, 1999a, *ibid.*).

A final group of the induced genes shows much weaker changes in p21<sup>-/-</sup> than in the wild-type cells (Figure 2B), indicating that regulation of these genes is mediated through p21. Since p21 induction in doxorubicin-treated HCT116 cells is p53-dependent, such genes also show diminished induction in p53<sup>-/-</sup> cells. The strongest p21 dependence among the tested genes is found for Cyclin D1. None of p21-dependent genes produces secreted growth inhibitors, but two of them encode secreted mitogenic/antiapoptotic proteins (prosaposin and TGF $\alpha$ ). Most of the genes that are downregulated in senescent HCT116 cells are known to be inhibited by p21 (Caulin *et al.*, *ibid.*). In agreement with this observation, such genes show decreased expression after doxorubicin treatment only in the wild-type but not in p21<sup>-/-</sup> or p53<sup>-/-</sup> cell lines (Figure 2B). Together with the genes that show p21-dependent induction, 20 of 31 tested genes that are affected by p53 knockout (excluding p21) are also affected to the same or greater degree by the knockout of p21. Therefore, p21, which until recently was not known to play a role in the regulation of gene expression, appears to be a major mediator of the corresponding effects of p53.

These results indicate that the genes identified herein can be used as markers for assessing compounds for their effects on cellular senescence and also for identifying compounds that induce the senescence phenotype by mechanisms that do not implicate p53, p21 or both.

#### EXAMPLE 4

##### Construction of Promoter-Reporter Gene Constructs That Are Induced in Senescent Cells and Screening for Agents that Induce Senescence in Tumor Cells

A cell-based screening assay is used to identify compounds that activate senescence-associated growth-inhibitory genes in p53-deficient tumor cells, without concurrent activation of secreted tumor-promoting factors. For this purpose, promoter constructs of different senescence-associated growth-inhibitory genes are constructed that drive expression of a chimeric GFP-luciferase reporter. Such a chimeric reporter was shown to be suitable for selection based on GFP fluorescence and for sensitive promoter

activity measurements based on luciferase chemiluminescence (Kotarsky *et al.*, 2001, *Anal. Biochem.* 288: 209-215). A similar chimeric reporter gene is commercially-available (Clontech, Palo Alto, CA). The promoter-reporter constructs are tested for inducibility by doxorubicin under conditions that activate the corresponding genes. The  
5 best-regulated promoter constructs are used to develop stably transfected cell lines, and cell lines identified that have the strongest induction of the reporter gene under conditions of drug-induced senescence.

Once suitable reporter cell lines are developed, optimized conditions for high throughput screening (HTS) of chemical libraries are determined based on luciferase  
10 activity of the reporter. This HTS assay is used to screen a chemical compound library (such as the Diversity Set of 1,990 compounds from the Developmental Therapeutics Program (DTP) of NCI). Positive compounds in this assay are then tested for their effects on expression of other genes associated with positive and negative aspects of accelerated senescence.

15 Seven senescence-associated growth-inhibitory genes are preferential targets for induction assays:

BTG1 is a tumor suppressor rearranged in t(8;12)(q24;q22) chromosomal translocation of B-cell leukemia and an inhibitor of cell proliferation (Rouault *et al.*, 1992, *EMBO J.* 11: 1663-1670). BTG1 was shown to be induced by DNA  
20 damage in different human tumor cell lines (Cortes *et al.*, 2000, *Mol. Carcinog.* 27: 57-64). Damage-induced BTG1 expression was shown by Cortes *et al.* and is shown herein to be independent of p53.

BTG2 (PC3/TIS21) is a BTG1 related antiproliferative gene (Rouault *et al.*, 1996, *Nat. Genet.* 14: 482-486). BTG1 is stress-responsive (Fiedler *et al.*, 1998, *Biochem. Biophys. Res. Commun.* 249: 562-565) and is also induced in different  
25 cell lines by DNA damage, growth factors and tumor promoters (Fletcher *et al.*, 1991, *J. Biol. Chem.* 266: 14511-14518). BTG2 was shown to be induced by p53 at the level of transcription (Rouault *et al.*, 1996, *ibid.*), but it is inducible by doxorubicin in p53<sup>-/-</sup> cells, albeit to a lesser degree than in the wild type cells.

IGF-binding protein 6 (IGFBP-6), a secreted inhibitor of IGF function and tumor cell growth (Bach, 1999, *Horm. Metab. Res.* 31: 226-234; Sueoka *et al.*, 2000, *Oncogene* 19: 4432-4436), was shown to be inducible by retinoids at the level of transcription (Dailly *et al.*, 2001, *Biochim. Biophys. Acta* 1518: 145-151). IGFBP-6 induction by doxorubicin shows no dependence on p53.

Amphiregulin is an EGF-related factor that was shown to inhibit the growth of several carcinoma cell lines, while promoting the growth of normal epithelial cells (Plowman *et al.*, 1990, *Mol. Cell Biol.* 10: 1969-1981). Amphiregulin is the major target of transcriptional induction by WT1 Wilms tumor suppressor gene (Lee *et al.*, 1999, *Cell* 98: 663-673) and is inducible by vitamin D3 (Akutsu *et al.*, 2001, *Biochem. Biophys. Res. Commun.* 281: 1051-1056). Amphiregulin induction by doxorubicin shows only moderate dependence on p53.

MIC-1 (pTGF- $\beta$ /PLAB/PDF/GDF15), a secreted growth-inhibitory member of TGF- $\beta$  superfamily, was shown to be induced by p53 at the level of transcription (Tan *et al.*, 2000, *Proc. Natl. Acad. Sci. USA* 97: 109-114) and was suggested to be a key mediator of paracrine growth-inhibiting effects of p53 (Kannan *et al.*, 2000, *FEBS Lett.* 470: 77-82). Surprisingly, MIC-1 induction by doxorubicin shows only weak dependence on p53.

Maspin, a secreted serine protease inhibitor, has been identified as a tumor suppressor whose expression is lost in many advanced breast cancers (Domann *et al.*, 2000, *Int. J. Cancer* 85: 805-810). Maspin shows very strong induction by DNA damage at the protein level, in doxorubicin-treated HCT116 cells, and others; Zou *et al.* (2000, *J. Biol. Chem.* 275: 6051-6054) showed maspin induction by drug treatment in four other tumor cell lines. Maspin expression is induced at the transcriptional level by p53 (Zou *et al.*, *ibid.*). Although p53 knockout strongly decreases Maspin induction by doxorubicin, such induction is still readily detectable in p53<sup>-/-</sup> cells.

EPLIN (Epithelial Protein Lost in Neoplasms), an actin-binding cytoskeletal protein, is expressed in almost all normal epithelial tissues but downregulated in 20 of 21 tested carcinoma cell lines. EPLIN inhibits cell proliferation, making it a

putative tumor suppressor (Maul & Chang, 1999, *Oncogene* 18: 7838-7841). EPLIN is induced not only in the senescent population of doxorubicin-treated HCT116 cells, but also in MCF7 breast carcinoma cells that undergo senescence-like growth arrest upon treatment with retinoids. Among all the genes in this group, EPLIN shows the weakest induction by doxorubicin in the unsorted cells; this induction is even further diminished in p21<sup>-/-</sup> and p53<sup>-/-</sup> cells. Although this pattern makes it potentially difficult to detect EPLIN induction upon drug treatment, strong increase in EPLIN expression in the sorted population of senescent cells suggests that its induction may be a particularly specific marker of senescence.

Functional promoter sequences have been published for all of these genes: BTG1 (Rodier *et al.*, 1999, *Exp. Cell Res.* 249: 337-348), BTG2 (Fletcher *et al.*, 1991, *ibid.*), IGFBP-6 (Dailly *et al.*, 2001, *ibid.*), amphiregulin (Lee *et al.*, 1999, *ibid.*), Maspin (Zou *et al.*, 2000, *ibid.*), MIC-1 (Tan *et al.*, 2000, *ibid.*), EPLIN (Gao *et al.*, 2000, *J. Cell Physiol.* 184: 373-379; EPLIN has two alternative promoters; the preferred promoter is the promoter corresponding to the longer  $\beta$  isoform that is preferentially expressed in HCT116 and MCF7 cells. Transcription of the corresponding genes is regulated by various factors (DNA damage, serum, differentiating agents, phorbol esters, tumor suppressors) through *cis*-regulatory elements in their promoters. In addition, Maspin has been shown to be silenced in breast cancers at the level of promoter methylation (Domann *et al.*, 2000, *ibid.*). Thus, it can be expected that senescence-associated changes in the expression of these genes will be reproducible in promoter constructs. Substantially all of these promoters share several common *cis*-regulatory sites, including AP-1, AP-4, ELK1 and GATA as revealed by examination of transcription factor binding sites in the corresponding promoter sequences, using MatInspector V2.2 program based on TRANSFAC 4.0 database. Together with the observed coregulation of these genes in drug-induced senescence, these observations support the likelihood of identifying agents that will stimulate all or most of these genes at the same time.

Reporter gene constructs are prepared by traditional cloning methods or by polymerase chain reaction (PCR) amplification of promoter sequences using primers designed from sequences flanking the corresponding promoters and human genomic

DNA as a template. The promoter sequences are cloned upstream of a suitable reporter gene, the most convenient of which is useful both as a selectable marker and as the basis for HTS. A commercially-available reporter comprising a chimera of green fluorescence protein and luciferase is most suitable for this purpose. This reporter is a chimeric protein  
5 formed by the Enhanced form of Green Fluorescent Protein (GFP) (commercially-available from Clontech) at the amino terminal end, fused with firefly luciferase at the carboxyl terminus. This chimeric reporter provides strong GFP fluorescence and high sensitivity of luciferase-based chemiluminescence assays. This gene is cloned into a promoterless vector in an orientation that a convenient cloning site or multiple cloning  
10 site is operably linked at the 5' end of the reporter gene, so that the promoters from the seven senescence-associated genes can be easily inserted into and thereby operably linked to the reporter gene.

Several of the tested genes are known to be inducible by p53. To select compounds that activate senescence-associated growth inhibitors through p53-  
15 independent mechanisms, p53-deficient cell lines will be used for screening. The primary cell line is a p53<sup>-/-</sup> derivative of HCT116 colon carcinoma cells (Bunz *et al.*, 1998, *Science* 282: 1497-1501), as described above. Promoter constructs that show positive results in this cell line are then tested in other p53-deficient tumor cell types, to confirm that the induction of these promoters is not unique to HCT116 cells (damage-  
20 responsiveness in a number of cell lines has already been demonstrated for BTG1, BTG2 and Maspin, and retinoid inducibility in breast carcinoma lines was shown for EPLIN and IGFBP-6). p53-mutated tumor cell lines are used, particularly those cell lines that develop the senescent phenotype upon doxorubicin treatment, including SW480 colon carcinoma, U251 glioma and Saos2 osteosarcoma (as disclosed by Chang *et al.*, 1999b, *ibid.*). Also  
25 used in these assays is a derivative of HT1080 fibrosarcoma wherein p53 function has been fully inhibited with a p53-derived genetic suppressor element GSE56 (as disclosed by Chang *et al.*, 1999a, *ibid.*).

These promoter-reporter constructs are used initially in transient transfection assays for the induction of luciferase activity by doxorubicin treatment. For  
30 normalization, the tested constructs are mixed with a construct carrying a different reporter gene under a constitutively expressed promoter (e.g.  $\beta$ -galactosidase transcribed from the CMV promoter). These mixtures are transfected (using electroporation) into

p53<sup>-/-</sup> HCT116 cells, which are then either untreated or treated with 200 nM doxorubicin. The activity of firefly luciferase and the control reporter gene ( $\beta$ -gal) are determined using commercially available assay kits, and the normalized values of firefly luciferase activity are compared between the treated and untreated cells. The promoter constructs  
5 that provide the highest expression and the best induction are determined from these assays.

Several promoter constructs showing at least 3-fold induction in transient transfection assays are transfected into p53<sup>-/-</sup> HCT116 cells, and stably transfected cell lines selected with puromycin. About 100 clonal transfectants from each tested construct  
10 are isolated and expanded to the size of close to 100,000 cells. At this stage, the picked lines are screened for activity by doxorubicin in 96-well plate assays (as described in more detail below). The best-inducible cell lines are expanded and subsequently characterized by repeated testing for both GFP and luciferase induction. Reporter cell lines are selected to maximize the absolute level of induced luciferase expression while  
15 retaining a high fold-induction, because high absolute luciferase expression minimizes the number of cells required to produce a detectable signal in HTS assays. Once developed, these optimal cell lines are analyzed with regard to the time course and doxorubicin dose-dependence of reporter expression and tested to verify senescence-specificity of the expression. The latter analysis is performed by labeling cells with PKH26 (a fluorophore  
20 related to PKH2 but having a red-shifted emission wave length), followed by doxorubicin treatment and release into drug-free media. Between 6-7 days after release, cells are analyzed with FACS by two-color analysis for PKH26 and GFP fluorescence. GFP fluorescence selectively associated with PKH26<sup>hi</sup> (senescent) cells is thereby determined without physical sorting. Finally, reporter expression inducibility in the selected cell lines  
25 is tested with senescence-inducing agents other than doxorubicin, other agents, such as ionizing radiation, cisplatin, aphidicolin or cytarabine (Chang *et al.*, 1999b, *ibid.*). The primary reporter cell line for subsequent compound screening is generated thereby, and secondary cell lines expressing the reporter from the promoters of different genes can be used for confirmatory assays.

30 The primary reporter cell line developed as described above is used to develop HTS assay. The dual GFP-luciferase nature of the reporter gene is especially convenient for conducting screening assays using the more sensitive luciferase-based



chemiluminescence assay, and the GFP fluorescence to confirm that the effect of a tested compound is not due to artifactual influence on the luciferase assay.

Primary screening will be carried out using the assay conditions established for doxorubicin and other senescence-inducing agents, and similarly to the procedures used  
5 by other investigators for luciferase-based screening of chemical libraries (Sohn *et al.*, 2001, *Ann. Surg.* 233: 696-703). Aliquots of 1 mM stocks of each compound in a compound library are added at a final 2  $\mu$ M concentration into a set of three 96-well plates containing cell culture media. These 96-well plates are then seeded with reporter cells and incubated at 37°C for the required period of time, with at least two reagent-free  
10 negative control wells and two doxorubicin-containing positive control wells per plate. After incubation, the plates are read (with no further manipulations) in the fluorescence reader, to identify the wells with substantial increase in GFP activity. The same plates are then processed for luciferase assay and read in a microplate luminometer. Luminometer readings on three plates are used to identify candidate positives, and compared with the  
15 results of GFP fluorescence. Positive compounds are re-tested in another set of assays prior to secondary screening. The nature of the assays for increased luciferase and GFP activity, which need to be expressed in live cells over the course of the assay, should eliminate highly cytotoxic compounds from the list of candidates.

Compounds that score as positive in the primary analysis are tested for their effect  
20 on the expression of different senescence-associated genes. Some of these assays are carried out using stably transfected cell lines, where the reporter gene is driven by promoters of other genes than the one in the primary reporter line. These simple reporter activation assays are warranted if a very large number of positives are detected in the primary assay. A second reporter line can be used to limit the number of compounds to  
25 those that are active with more than one promoter. If the number of positive compounds after the primary screen is low, however, this secondary screening step is unnecessary and the positive compounds are used for direct analysis of the compounds on gene expression.

On addition and prior to extensive further screening the minimal concentration of the compound that produces a strong increase in the reporter assay is determined. This  
30 concentration is also tested on p53-/- HCT116 cells for its effect on the expression of the endogenous senescence-associated genes. In these assays, RNA is extracted before and after treatment, and expression of different senescence-associated genes is analyzed, for

example by quantitative RT-PCR (as disclosed by Noonan *et al.*, 1990) that allows expression levels for multiple genes among a set of RNA samples to be compared. A single RT-PCR assay uses about 50 ng of total cellular RNA, which makes it possible to carry out about 100 assays starting from 5  $\mu$ g of total RNA, an amount that is typically  
5 used for a single lane in northern hybridization. In this assay,  $\beta$ -actin is used as a normalization standard, since its expression is unaltered in senescent cells, according to northern and western blots.

RT-PCR primers and assay conditions for 63 genes that are up- or downregulated in doxorubicin-induced accelerated senescence (Chang *et al.*, 2001, *ibid.*) are disclosed in  
10 Table 3. These assays are used to test if the positive compounds can activate not only the growth-inhibitory genes that are described above, but also other senescence-associated growth regulators, such as WIP1, CD44, Jagged1, and also several genes that are known to be downregulated in cancers relative to normal cells and then upregulated in senescent tumor cells, such as P-cadherin, desmoplakin and desmoyokin. The latter genes are likely  
15 to be co-regulated with senescence-associated growth inhibitors that are downregulated in cancers (such as EPLIN or Maspin). On the other hand, it is expected that compounds will be found that will not induce p21 or the potentially pathogenic proteins that are upregulated in doxorubicin-induced senescence, such as secreted tumor-promoting factors TGF $\alpha$ , CYR61 and prosaposin, proteases such as kallikrein-7 or calpain L2, and plaque-  
20 forming proteins, such as Alzheimer's  $\beta$ -amyloid precursor and BRI. Positive compounds are also assayed for the effects of the compounds on genes that are downregulated in senescent cells, such as tumor-specific transmembrane protein STEAP, and genes involved in cell proliferation (*e.g.* Ki-67, Topoisomerase II $\alpha$ , CDC2, PLK1, MAD2, Thymidylate synthetase, Ribonucleotide reductase M1). Inhibition of the latter  
25 genes will be indicative of a cytostatic effect of the tested compound, which will be tested in separate assays (see below).

If this analysis reveals a compound that has the desired effect on gene expression, analyses are performed to determine how the compound affects cell growth. This analysis will be carried out both by standard cell proliferation assays, and by an assay that  
30 evaluates the cytostatic and cytotoxic components of the antiproliferative effect. In this assay, cells are labeled with PKH2, treated with the test compound either continuously or for a limited period of time (*e.g.* 24 hrs), and analyzed after the period of time

corresponding to three cell doublings. For this analysis, attached and floating cells will be combined and stained with propidium iodide (PI), which stains only membrane-compromised (dead) cells. The stained cells are then analyzed by FACS for changes in PKH2 fluorescence and for the fraction of PI-positive cells, next to the control sample of untreated cells that were labeled with PKH2 at the same time. Increased PKH2 fluorescence relative to control cells indicates the inhibition of cell division (cytostatic effect) and increased PI+ fraction indicates the cytotoxic effect. Compounds with preferentially cytostatic (rather than cytotoxic) effect on tumor cells are of particular interest, because such an effect is expected from the specific activation of the senescence program.

If a prototype compound with desired properties is found, a library of derivatives from this compound is prepared, which is then screened to find more effective agents. Such agents are evaluated as prototype drugs by preclinical studies.

#### EXAMPLE 5

##### **Construction of Promoter-Reporter Gene Constructs and Screening for Agents That Prevent the Induction of Pathogenic Genes Associated with Anticancer Agent-Induced Senescence**

The results disclosed herein show that certain genes are induced by treatment with cytotoxic drugs that have been associated with diseases of aging and paracrine growth-stimulating effects, especially tumor cell growth stimulation. These genes include cyclin D1, serum-inducible kinase, CYR61, prosaposin, transforming growth factor  $\alpha$  (TGF $\alpha$ ), kallikrein 7, calpain-L2, neurosin, plasminogen activator, urokinase, amyloid beta (A4) precursor protein ( $\beta$ APP), and integral membrane protein 2B (BRI/ITM2B). Promoters from these genes can be used to make reporter gene constructs in like manner as disclosed in Example 4 for other senescence-associated genes. These constructs can then be used to assay reporter gene induction by cytotoxic drug treatment in the presence and absence of a test compound.

Functional promoter sequences have been published for all of these genes: cyclin D1 (Motokura & Arnold, 1993, *Genes Chromosomes Cancer* 7: 89-95); CYR61 (Latinkic *et al.*, 1991, *Nucleic Acids Res.* 19: 3261-7); prosaposin (Sun *et al.*, 1998, *Gene* 218: 23-34); transforming growth factor  $\alpha$  (TGF $\alpha$ ; Raja *et al.*, 1991, *Mol. Endocrinol.* 5: 514-20);

kallikrein 7 (Yousef *et al.*, 2000, *Gene* 254: 119-128); calpain-L2 (Suzuki *et al.*, 1995, *Biol Chem Hoppe Seyler*. 376: 523-9); plasminogen activator urokinase (Riccio *et al.*, 1985, *Nucleic Acids Res.* 13: 2759-71); and amyloid beta (A4) precursor protein ( $\beta$ APP; Lahiri & Robakis, 1991, *Brain Res. Molec. Brain Res.* 9: 253-257).

5           Reporter gene constructs are prepared by modification of the methods described in Example 4. Senescence is induced in transient and stably-transfected cells, typically by contacting the cells with a senescence-inducing concentration of doxorubicin or other cytotoxic agent. These experiments are used to establish levels of reporter gene induction in the absence of a test compound.

10           The promoter-reporter constructs are tested for inducibility by doxorubicin under conditions that activate the corresponding genes. The best-regulated promoter constructs are used to develop stably transfected cell lines, and cell lines identified that have the strongest induction of the reporter under the conditions of drug treatment, as described in Example 4.

15           Experiments are also performed in the presence of a test compound in an identical manner as experiments performed in the absence of the test compound. Experiments are typically performed at a variety of concentrations of the test compound in cells induced with the same concentration of cytotoxic agent, and expression of the reporter gene determined and compared to reporter gene expression in cells induced with that  
20           concentration of cytotoxic agent in the absence of the test compound.

          The results of these experiments identify test compounds that reduce, inhibit or prevent senescence-associated induction of disease-promoting senescence-associated genes in cells treated with a cytotoxic drug, and effective concentrations thereof. These results provide compounds useful for preventing induction of disease-promoting,  
25           particularly tumor cell growth-stimulating genes as a consequence of cytotoxic agent-induced senescence associated with conventional cancer treatments.

          It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims.

**Table 1. Genes downregulated in senescent relative to proliferating cell fractions in HCT116 cells separated after doxorubicin treatment**  
(genes confirmed by RT-PCR are shown in boldface)

Gene Name	Accession Number	Effects of:		Notes	B.D.E. <sup>b</sup>
		p53	p21		
Transcription factors and cofactors					
HFH-11/Trident/Wim/MPP2	U74612		↓ <sup>1</sup>	Positive cell growth regulator <sup>2</sup> , downregulated in aging <sup>3</sup>	-3.3
AND-1	AJ006266			WD repeat, HMG-box	-2.4
Structure specific recognition protein 1 (SSRP1)	M86737		↓ <sup>1</sup>	Transcription elongation factor	-2.3
Histone acetyltransferase 1 (HAT1)	AF030424		↓ <sup>d</sup>	Transcription cofactor	-2.1
Zinc finger protein, Y-linked (ZFY)	M30607			Testis determination	-2.1
Mitosis/DNA segregation					
Ki-67 antigen	X65550		↓ <sup>d</sup>	Chromatin condensation	-4.9
XCAP-C condensin homolog	NM_005496			Chromatin condensation	-4.2
Centromere protein F (CENP-F)	NM_005196		↓ <sup>1</sup>	Kinetochore component, downregulated in aging <sup>3</sup>	-3.8
XCAP-H condensin homolog	D38553		↓ <sup>1</sup>	Chromatin condensation	-3.7
BUBR1/BUB1B	AF053306		↓ <sup>1</sup>	Kinetochore, spindle checkpoint control	-3.6
Kinesin-like DNA binding protein (Kid/Obp-2)	AB017430		↓ <sup>d</sup>	Kinetochore	-3.1
AIM-1/AIK-2	NM_004217		↓ <sup>1</sup>	Centrosome regulator	-3.1
Lamin B receptor	L25941	↓ <sup>d</sup>		Nuclear envelope assembly	-3
Apoptosis inhibitor 4 (survivin)	U75285		↓ <sup>d</sup>	Centrosome; protects from mitosis-associated apoptosis	-2.9
CDC2	X05360	↓ <sup>5</sup>	↓ <sup>1</sup>	Mitosis initiation	-2.7
CDC20	AW411344		↓ <sup>d</sup>	APC activation/anaphase onset, downregulated in aging <sup>3</sup>	-2.6
Mitotic kinesin-like protein-1	H63163			Spindle movement	-2.5
Centromere protein E (CENP-E)	Z15005		↓ <sup>d</sup>	Kinetochore	-2.5
ZW10 Interactor (hZwint-1/MPP5)	AW409765		↓ <sup>1</sup>	Kinetochore	-2.5

Thyroid hormone receptor interactor 13 (TRIP13)/HPV16 E1 binding protein	AA134541		↓ <sup>1</sup>	homolog of a yeast pachytene checkpoint protein	-2.4
Breast cancer 1 (BRCA1)	L78833	↓ <sup>6</sup>		Centrosome duplication regulator, tumor suppressor	-2.3
Homolog of rough deal (Rod) protein of Drosophila	AF070553			Chromosome segregation	-2.3
AIK-1/AIM-2/STK15	NM_003600		↓ <sup>1</sup>	Centrosome regulator, protooncogene amplified in cancers <sup>7</sup>	-2.1
MAD2	NM_002358	↓ <sup>4</sup>	↓ <sup>1</sup>	Kinetochore, spindle checkpoint control	-2.1
Topoisomerase IIα	AF071747	↓ <sup>4</sup>	↓ <sup>1</sup>	DNA and chromosome segregation	-2.1
Lamin B2	M94363		↓ <sup>1</sup>	Nuclear envelope assembly	-2.1
Pericentrin	AI970199			Centrosome	-2
Thymopoietin	U18271		↓ <sup>1</sup>	Nuclear envelope assembly	-2
PK506-binding protein 5	U71321			Homologous to rodent TP2 involved in testis-specific chromatin condensation	-2
Polo-like kinase (PLK1)	U01038		↓ <sup>1</sup>	Controls initiation and several other stages of mitosis, downregulated in aging <sup>3</sup>	ND <sup>c</sup>
DNA replication/chromatin assembly					
Ribonucleotide reductase M1 (RRM1)	NM_001033		↓ <sup>1</sup>	Nucleotide synthesis	-3.4
High-mobility group protein 1 (HMG1)	AW160834		↓ <sup>1</sup>	Chromatin component	-3.4
Thymidine kinase 1	NM_003258		↓ <sup>1</sup>	Nucleotide synthesis	-3.3
MCM7/CDC47	D55716	↓ <sup>4</sup>	↓ <sup>1</sup>	Replication licensing factor component	-3.3
Thymidylate synthase	NM_001071		↓ <sup>1</sup>	Nucleotide synthesis, downregulated in aging <sup>3</sup>	-3.2
MCM2 (mitotin)	AW264268		↓ <sup>4</sup>	Replication licensing factor component	-2.8
Replication factor C (activator 1) (36.5kD)	AI651635, AW651734		↓ <sup>1</sup>	PCNA clamp formation	-2.7,-2.4 <sup>c</sup>
High-mobility group protein 2 (HMG2)	X62534	↓ <sup>4</sup>	↓ <sup>1</sup>	Chromatin component, downregulated in aging <sup>3</sup>	-2.5
Replication protein A3 (14kD)	NM_002947		↓ <sup>4</sup>	Single-stranded DNA binding protein, involved in replication and repair	-2.1
Gamma-glutamyl hydrolase (folypolyglutaminyl hydrolase)	NM_003878			Folate metabolism regulator	-2
MCM3	NM_002388		↓ <sup>4</sup>	Replication factor	-2

DNA repair				
<b>HEX1 (RAD2 homolog)</b>	AF042282	↓ <sup>1</sup>	Exonuclease	-3.7
Flap endonuclease 1 (FEN1, RAD2 homolog)	AW246270	↓ <sup>d</sup>	Exonuclease, downregulated in aging <sup>3</sup>	-3
RAD51 homolog	D14134	↓ <sup>d</sup>	Similar to E. coli RecA	-2.4
T(12;16) malignant liposarcoma fusion (TLS/FUS)	S62140	↓ <sup>d</sup>	Retinoid-inhibited, protooncogene <sup>8</sup>	-2.2
RNA processing/trafficking				
Heterogeneous nuclear ribonucleoprotein H1	NM_005520	↓ <sup>d</sup>		-2.1
<b>Acidic protein rich in leucines (APRIL)</b>	Y07570	↓ <sup>d</sup>	RNA stability	-2.1
Pre-mRNA cleavage factor Im (25kD)	AA738354	↓ <sup>d</sup>		-2
Heterogeneous nuclear ribonucleoprotein G	Z23064			-2
Heterogeneous nuclear ribonucleoprotein A2/B1	NM_002137	↓ <sup>d</sup>		-2
Heterogeneous nuclear ribonucleoprotein A1	AA173135	↓ <sup>d</sup>		-2
Proliferation-associated				
Insulin induced gene 1 (INSIG1/CL-6)	AW663903		Liver regeneration	-2.3
Hyaluronan-mediated motility receptor (RHAMM)	U29343	↓ <sup>1</sup>	Cell motility, oncogenic activity <sup>9</sup>	-2.1
FSH primary response (LRPR1)	NM_006733		FSH proliferative response	-2.1
<b>Six-transmembrane epithelial protein of the prostate (STEAP)</b>	AC004969		Overexpressed in carcinomas, potential membrane transporter <sup>10</sup>	-2.1
Other				
Rabkinesin-6	NM_005733	↓ <sup>d</sup>	Golgi, intracellular transport	-3
Vaccinia related kinase 1	AA312869	↓ <sup>d</sup>	p53 phosphorylation, possible Mdm-2 interference	-3
Protein kinase C, theta	L07032	↓ <sup>d</sup>	Signal transduction	-2.4
Ubiquitin carrier protein	A1571293		Proteolysis, downregulated in aging <sup>3</sup>	-2.2
Actin, γ1	NM_001614			-2.1
<b>KIAA0008</b>	D13633	↓ <sup>1</sup>		-4.6
<b>KIAA0101</b>	D14657	↓ <sup>4</sup>		-4
KIAA0056	AF070553			-2.3
KIAA0225	D86978			-2.1

- <sup>a</sup> Known changes in gene expression upon ectopic overexpression of p53 or p21
- <sup>b</sup> B.D.E., balanced differential expression (from Incyte UniGem V 2.0 hybridization analysis), in almost all cases underestimates the actual fold difference observed by RT-PCR
- <sup>c</sup> Two clones in the array were found to be derived from the same gene, the B.D.E. values for both clones are shown
- <sup>d</sup> effects of p21 induction in HT1080 fibrosarcoma cells, as determined by microarray hybridization (our unpublished data, not included in the original report <sup>1</sup>).
- <sup>e</sup> not detected by microarray hybridization but identified by RT-PCR

## 10 Reference List

1. B. D. Chang et al., *Proc. Natl. Acad. Sci. USA* 97, 4291-4296 (2000).
2. H. Ye, A. X. Holterman, K. W. Yoo, R. R. Franks, R. H. Costa, *Mol. Cell Biol.* 19, 8570-8580 (1999).
3. D. H. Ly, D. J. Lockhart, R. A. Lerner, P. G. Schultz, *Science* 287, 2486-2492 (2000).
4. R. Zhao et al., *Genes Dev.* 14, 981-993 (2000).
5. K. Kannan, N. Amariglio, G. Rechavi, D. Givol, *FEBS Lett.* 470, 77-82 (2000).
6. P. Arizti et al., *Mol. Cell Biol.* 20, 7450-7459 (2000).
7. H. Zhou et al., *Nat. Genet.* 20, 189-193 (1998).
8. D. Perrotti et al., *EMBO J.* 17, 4442-4455 (1998).
9. C. L. Hall et al., *Cell* 82, 19-26 (1995).
10. R. S. Hubert et al., *Proc Natl. Acad. Sci. U.S.A* 96, 14523-14528 (1999).



**Table 2. Genes upregulated in senescent relative to proliferating cell fractions in HCT116 cells separated after doxorubicin treatment (genes confirmed by RT-PCR are shown in boldface)**

Table 2A					
Gene Name	Accession Number	Effects of <sup>a</sup> :		Notes	B.D.E. <sup>b</sup>
		p53	p21		
Transcription factors					
X-box binding protein 1 (XBP-1/HTF/TREB)	AW021229			bZIP domain, c-Jun family, dimerizes with Fos <sup>1</sup>	3.9
Activating transcription factor 3 (ATF3)	N39944	↑ <sup>2</sup>		bZIP domain, dimerizes with c-Jun <sup>3</sup>	3.3
C-JUN	AI078377			AP-1, stress response <sup>4</sup>	2.5
ELF-1	AW503166			ets domain factor, expressed in lymphoid and epithelial tissues <sup>5</sup>	2.4
Ring finger protein 3 (RNF3)	AA403225		↑ <sup>d</sup>	homolog of 73Ah regulator of Drosophila	2.3
Homolog of Drosophila muscleblind B protein (MBLL)	AF061261			C3H-type zinc finger protein	2.3
SOX9/SRY (sex-determining region Y)	NM_000346			HMG domain, retinoid-inducible <sup>6</sup> , involved in chondrocyte differentiation <sup>7</sup>	2.2
Sjogren syndrome antigen A2 (60kD, ribonucleoprotein SS-A/Ro)	U44388			Putative transcription regulator	2.1
Core promoter element binding protein (CPBP/ZF9/KLF8)	AL037865			Kruppel-like family transcription factor, activates keratin-4 promoter <sup>8</sup>	2
Growth inhibitors, intracellular					
Epithelial Protein Lost in Neoplasms (EPLIN)	AL048161			Decreased in multiple carcinomas <sup>11</sup>	3.5
B-cell translocation gene 1 (BTG1)	AI560266			Tumor suppressor <sup>12</sup>	2.8
B-cell translocation gene 2 (BTG2)	NM_006763	↑ <sup>13</sup>		Tumor suppressor <sup>13</sup>	2.1
WIP1	NM_003620	↑ <sup>14</sup>		p53-inducible protein phosphatase <sup>14</sup>	2
Growth inhibitors, secreted					
Maspin	AA316156, AI435384	↑ <sup>15</sup>		Serine protease inhibitor, downregulated in neoplasms, inhibits tumor growth, metastasis, angiogenesis <sup>16</sup> , upregulated in aging <sup>17</sup>	5.2, 3.3 <sup>c</sup>

<b>MIC-1 (Prostate differentiation factor, PTGF-<math>\beta</math>, PLAB)</b>	AB000584	$\uparrow^{18}$	TGF- $\beta$ family, downregulated in cancers, induces growth arrest and apoptosis <sup>19</sup>	2.9
<b>Insulin-like growth factor binding protein 6 (IGFBP-6)</b>	AA675888		Retinoid-inducible <sup>20</sup>	2.7
<b>Amphiregulin</b>	NM_001657		EGF/TGF $\alpha$ family secreted factor, promotes growth of normal epithelial cells but inhibits carcinomas <sup>21</sup> , WTI-inducible <sup>22</sup>	2.3
<i>Other growth regulators</i>				
<b>CD44 antigen</b>	X66733, X55150		Adhesion molecule, growth modulator <sup>23</sup> , upregulated in aging <sup>17</sup>	3.9, 2.1 <sup>c</sup>
<b>Jagged-1</b>	U61276		Notch ligand, stem cell growth, angiogenic factor <sup>24</sup>	2
<i>Cell adhesion and cell-cell contact</i>				
<b>P-cadherin</b>	NM_001793		Lost in prostate cancer <sup>26</sup>	2.9
<b>Desmoplakin (DPI, DPII)</b>	J05211		Decreased in neoplasms <sup>27</sup> , upregulated in aging <sup>38</sup>	2.4
<b>PM5 protein (collagenase-related)</b>	X57398		Homologous to cell adhesion proteins	2.2
<b>CD63/ME49I antigen</b>	X62654			2.1
<b>Mac-2 binding protein</b>	X79089	$\uparrow^{28}$	ECM organizer <sup>39</sup>	2
<b>Occludin</b>	U53823		Tight junction protein	2.1
<i>ECM receptors</i>				
<b>Integrin <math>\beta 4</math></b>	X53587			2.6
<b>Laminin, <math>\alpha 3</math> (nicein/kalinin/BM600/epilegrin)</b>	L34155			2.4
<b>Syndecan 4 (amphiglycan, ryudocan)</b>	D79206, NM_002999		Involved in wound repair and angiogenesis <sup>40</sup>	2.3, 2.2 <sup>c</sup>
<b>Integrin <math>\alpha 6</math></b>	X53586			2.2
<i>Transmembrane signaling</i>				
<b>AHNAK nucleoprotein (desmoyokin)</b>	M80899		Activates PLC- $\gamma^1$ , decreased in neuroblastomas <sup>42</sup>	2.1
<b>CD24 antigen</b>	A1745625		Mucin-like glycoprotein, upregulated in breast carcinoma <sup>43</sup>	2.1
<b>Lipocortin-2 (annexin A2)</b>	W53011		Substrate of src tyrosine kinase	2

<i>Ion transport and ion exchange</i>					
Phospholemman-like, 8kD (MAT-8)	AA826766			Chloride channel activator	2.3
Ferritin, heavy polypeptide 1	AW575826		↑ <sup>d</sup>	Iron storage	2.8
Caveolin 2	AI093287			Membrane compartmentalization	2.2
Neurogranin	Y09689		↑ <sup>d</sup>	Calmodulin binding protein, neural	2.2
H1 chloride channel	AI381979			Colocalizes with caveolin <sup>44</sup>	2
<i>Intracellular trafficking, cytoskeletal and scaffolding</i>					
Interferon-induced protein 56 (IFI-56K/P56)	NM_001548			Tetratricopeptide protein, Int6 interaction <sup>45</sup>	3.2
Major vault protein (lung resistance protein, LRP)	X79882			Stress response, multidrug resistance	2.4
Macrophin (microfilament and actin filament cross-linker protein)	AB029290			Cytoskeletal	2.4
Microtubule-associated protein 1B (MAP1B)	L06237			Cytoskeletal, CK2 substrate	2
<i>Proapoptotic</i>					
<u>NOXA</u>	D90070		↑ <sup>46</sup>	Bcl2 family member <sup>46</sup>	2.7
<u>Fas antigen/APO-1</u>	M67454		↑ <sup>47</sup>	Apoptotic signal receptor	2.3
<i>Keratins</i>					
<u>Keratin 18</u>	X12881			Antiapoptotic <sup>48</sup>	4
Keratin 8	X74929		↑ <sup>49</sup>	Antiapoptotic <sup>48</sup>	3.4
Keratin 2A	AF019084				2.9
Keratin 7	M13955, AA307373				2.6 2.1 <sup>c</sup>
Keratin 15	NM_002275				2.3
Keratin 6B	L42611				2.1
<i>Other</i>					
High mobility group protein HMG2 homolog	AI191623				5.4
U1 small ribonucleoprotein 1 SNRP homolog	AI400786				3.7
Retinaldehyde dehydrogenase 3 (ALDH6/RALDH3)	U07919			Retinoic acid synthesis	3.2

Tumor differentially expressed 1 (TDE1)	NM_006811			Transmembrane protein, homologous to mouse gene increased in testicular tumors <sup>30</sup>	2.4
Apolipoprotein E	K00396			Alzheimer's, atherosclerosis	2
Inocyte EST	X62654				2.1
23815 human mRNA	U90916				2.1
<b>Table 2B</b>					
<i>Growth regulators, intracellular</i>					
p21 (Waf1/Cip1/Sdi1)	AA481712	↑ <sup>9</sup>		Pleiotropic inhibitor of cyclin-CDK complexes, inhibits or stimulates various transcription factors and cofactors <sup>10</sup>	5.1
Cyclin D1 (Bcl-1)	M73554, X59798	↑ <sup>25</sup>	↑ <sup>25</sup>	G1/S transition, coregulated with p21 in cancers <sup>26</sup>	2.8, 2.2 <sup>c</sup>
Serum-inducible kinase (Snk, polo-like)	NM_006622			Putative cell growth regulator	2.2
<i>Mitogenic/antiapoptotic factors, secreted</i>					
<u>CYR61</u>	Y12084			Mitogenic/angiogenic factor <sup>27</sup>	3.3
<u>Prosaposin</u>	J03015		↑ <sup>28</sup>	Antiapoptotic/mitogenic <sup>29</sup> upregulated in aging <sup>30</sup>	2.3
Transforming growth factor α (TGFα)	X70340	↑ <sup>31</sup>		EGF-related mitogen <sup>32</sup>	2
<i>Proteases</i>					
Kallikrein 7 (serine protease 6)	L33404			Upregulated in ovarian carcinoma <sup>33</sup>	3.2
<u>Calpain-L2</u>	M23254				2.3
Neurosin (serine protease 9, Zyme, Protease M)	NM_002774			Downregulated in breast cancers <sup>34</sup> , upregulated in ovarian carcinoma <sup>35</sup>	2
Plasminogen activator, urokinase	D11143				2
<i>Other</i>					
Amyloid beta (A4) precursor protein (βAPP)	X06989		↑ <sup>38</sup>	Alzheimer's disease amyloid precursor	2
Integral membrane protein 2B (BRU/ITM2B)	AW131784			Amyloid precursor in familial British dementia <sup>31</sup>	2

- <sup>a</sup> Known changes in gene expression upon ectopic overexpression of p53 or p21
- <sup>b</sup> B.D.E., balanced differential expression (from Incyte UniGem V 2.0 hybridization analysis), in almost all cases underestimates the actual fold difference observed by RT-PCR
- <sup>c</sup> Two clones in the array were found to be derived from the same gene, the B.D.E. values for both clones are shown
- <sup>d</sup> effects of p21 induction in HT1080 fibrosarcoma cells, as determined by microarray hybridization (our unpublished data, not included in the original report<sup>28</sup>).

# Reference List

1. A. M. Reimold et al., *Genes Dev.* 14, 152-157 (2000).
2. T. Hai, C. D. Wolfgang, D. K. Marsee, A. E. Allen, U. Sivaprasad, *Gene Expr.* 7, 321-335 (1999).
3. C. D. Wolfgang, G. Liang, Y. Okamoto, A. E. Allen, T. Hai, *J. Biol. Chem.* 275, 16865-16870 (2000).
4. D. Bohmann et al., *Science* 238, 1386-1392 (1987).
5. A. G. Bassuk, K. P. Barton, R. T. Anandappa, M. M. Lu, J. M. Leiden, *Mol. Med.* 4, 392-401 (1998).
6. O. J. Marshall and V. R. Harley, *Mol. Genet. Metab.* 71, 455-462 (2000).
7. W. Huang, U. I. Chung, H. M. Kronenberg, B. de Crombrughe, *Proc. Natl. Acad. Sci. U.S.A.* 98, 160-165 (2001).
8. J. Okano et al., *FEBS Lett.* 473, 95-100 (2000).
9. W. S. El Deiry et al., *Cell* 75, 817-825 (1993).
10. G. P. Dotto, *Biochim. Biophys. Acta* 1471, M43-M56 (2000).
11. R. S. Maul and D. D. Chang, *Oncogene* 18, 7838-7841 (1999).
12. J. P. Rouault et al., *EMBO J.* 11, 1663-1670 (1992).
13. J. P. Rouault et al., *Nat. Genet.* 14, 482-486 (1996).
14. M. Fiscella et al., *Proc. Natl. Acad. Sci. U.S.A.* 94, 6048-6053 (1997).
15. Z. Zou et al., *J. Biol. Chem.* 275, 6051-6054 (2000).
16. F. E. Domann, J. C. Rice, M. J. Hendrix, B. W. Futscher, *Int. J. Cancer* 85, 805-810 (2000).
17. C. K. Lee, R. Weindruch, T. A. Prolla, *Nat. Genet.* 25, 294-297 (2000).
18. M. Tan, Y. Wang, K. Guan, Y. Sun, *Proc. Natl. Acad. Sci. U.S.A.* 97, 109-114 (2000).
19. P. X. Li et al., *J. Biol. Chem.* 275, 20127-20135 (2000).
20. Y. P. Dailly, Y. Zhou, T. A. Linkhart, D. J. Baylink, D. D. Strong, *Biochim. Biophys. Acta* 1518, 145-151 (2001).

21. G. D. Plowman et al., *Mol. Cell Biol.* 10, 1969-1981 (1990).
22. S. B. Lee et al., *Cell* 98, 663-673 (1999).
23. P. Herrlich et al., *Ann. N.Y. Acad. Sci.* 910, 106-118 (2000).
24. L. Walker et al., *Stem Cells* 17, 162-171 (1999).
25. X. Chen, J. Bargonetti, C. Prives, *Cancer Res.* 55, 4257-4263 (1995).
26. J. S. de Jong, P. J. van Diest, R. J. Michalides, J. P. Baak, *Mol. Pathol.* 52, 78-83 (1999).
27. A. M. Babic, M. L. Kireeva, T. V. Kolesnikova, L. F. Lau, *Proc. Natl. Acad. Sci. U.S.A.* 95, 6355-6360 (1998).
28. B. D. Chang et al., *Proc. Natl. Acad. Sci. U.S.A.* 97, 4291-4296 (2000).
29. M. Hiraiwa, E. M. Taylor, W. M. Campana, S. J. Darin, J. S. O'Brien, *Proc. Natl. Acad. Sci. U.S.A.* 94, 4778-4781 (1997).
30. P. P. Mathur et al., *Biochem. Mol. Biol. Int.* 34, 1063-1071 (1994).
31. T. H. Shin, A. J. Paterson, J. E. Kudlow, *Mol. Cell Biol.* 15, 4694-4701 (1995).
32. V. Kumar, S. A. Bustin, I. A. McKay, *Cell Biol. Int.* 19, 373-388 (1995).
33. H. Tanimoto et al., *Cancer* 86, 2074-2082 (1999).
34. A. Anisowicz, G. Sotiropoulou, G. Stenman, S. C. Mok, R. Sager, *Mol. Med.* 2, 624-636 (1996).
35. H. Tanimoto, L. J. Underwood, K. Shigenasa, T. H. Pamley, T. J. O'Brien, *Tumour Biol.* 22, 11-18 (2001).
36. D. F. Jarrard et al., *Clin. Cancer Res.* 3, 2121-2128 (1997).
37. A. Hiraki et al., *Br. J. Cancer* 73, 1491-1497 (1996).
38. D. H. Ly, D. J. Lockhart, R. A. Lerner, P. G. Schultz, *Science* 287, 2486-2492 (2000).
39. T. Sasaki, C. Brakebusch, J. Engel, R. Timpl, *EMBO J.* 17, 1606-1613 (1998).
40. F. Echtermeyer et al., *J. Clin. Invest.* 107, R9-R14 (2001).
41. F. Sekiya, Y. S. Bae, D. Y. Jhon, S. C. Hwang, S. G. Rhee, *J. Biol. Chem.* 274, 13900-13907 (1999).
42. E. Shivelman, F. E. Cohen, J. M. Bishop, *Proc. Natl. Acad. Sci. U.S.A.* 89, 5472-5476 (1992).
43. M. Fogel et al., *Cancer Lett.* 143, 87-94 (1999).
44. J. C. Edwards, *Am. J. Physiol.* 276, F398-F408 (1999).
45. J. Guo and G. C. Sen, *J. Virol.* 74, 1892-1899 (2000).
46. E. Oda et al., *Science* 288, 1053-1058 (2000).
47. M. Muller et al., *J. Exp. Med.* 188, 2033-2045 (1998).
48. C. Caulin, C. F. Ware, T. M. Magin, R. G. Oshima, *J. Cell Biol.* 149, 17-22 (2000).
49. T. Mukhopadhyay and J. A. Roth, *Anticancer Res.* 16, 105-112 (1996).
50. M. Bossolasco, M. Lebel, N. Lemieux, A. M. Mes-Masson, *Mol. Carcinog.* 26, 189-200 (1999).
51. R. Vidal et al., *Nature* 399, 776-781 (1999).

Table 3  
PCR Amplification Primer Sequences

Gene	Sense (5'-3')	SEQ ID NO	Antisense (5'-3')	SEQ ID NO
AIK1	TGGAATATGCACCACTTGA	1	TTCTCTGAGCATTTGGCCTCT	63
AIK2 (AIM1)	TGGACACCCGACATCTTA	2	GCTCTTCTGACAGCTCCTTGTA	64
APRIL	TGCCCCAGCTTACCTACTG	3	AATCCATGAGCAGTCCAACC	65
BRCA1	AAGACAGAGCCCCAGAGTCA	4	GACCTTGGTGGTTTCTTCCA	66
BUBR1	GAAGCCGAGCTATTGACCAG	5	GCCTGTGATAAATGGCATCCT	67
CDC2	AAGCCGGGATCTACCATACC	6	GGCCAAAATCAGCCAGTTTA	68
CDC20	GAGGTGCAGCTATGGGATGT	7	TGTAATGGGGAGACCAGAGG	69
CDC47	CGACAGGTGGTACAGGGTTT	8	CAGCCATCTTGTGCAACTCA	70
CENP-E	GTTGATCTTGCAGGCAGTGA	9	TCACCAGCATCCGTGTTAAG	71
Condensin H (XCAP-H)	ACGACACCTCCAACTTTTGC	10	CCGCTAAGCATCTTCTCGTC	72
GRCC8	CAGGTGTTTTCCAAAGGAGGA	11	GCTGTGAGTCCCAGTTTGGT	73
HEX1 (RAD2)	ACTGCGTGGGATTGGATTAG	12	TCTTGAATGGGCAGGCATAG	74
HFH-11B (MPP2, Trident)	TTACACAGCATCATCACAGCA	13	TCGAAGGCTCCTCAACCCTTA	75
HMG1	AGGGAGTTGTCAAGGCTGAA	14	CTGTGCCCAAAACAAGAACCT	76
HPV 16E1-BP (TRIP13)	GACTCACAGCCCCATCGATT	15	CACCAGGGCGTCTTTATCAT	77
Ki67	CAGACTCCATGTGCCTGAGA	16	CCCTGGAGAACATAGGCAAA	78
KIAA0008	GCCAAAGGCAATGAAACTA	17	ACCTGCTTGTGCTTGAGT	79
KIAA0101	CTGAAGAGGCAGGAAGCAGT	18	TGGCACCATTCCAATAATCA	80
KIAA0166 (rod)	GCAGCTCAAAAGTCCACATCA	19	GGCCTTGGCCTCTTTAGAAT	81
MAD2	TGGCCGAGTTCTTCTCATTC	20	CGCACITTCCTCAGAATTGGT	82

Gene	Sense (5'-3')	SEQ ID NO	Antisense (5'-3')	SEQ ID NO
Pericentrin	CAGCCAGGTCCTCCATTGT	21	AGCTTGGTCTCCAGCATAA	83
PLK1	AAGAGATCCCGGAGGTCCTA	22	TCCACACAGGGTCTTCTTC	84
Ribonucleotide reductase M1	ACCAGCAAAGATGAGGTTC	23	GCATCGGGGCAATAAGTAAA	85
STEAP	GCCCTTCAGAACTTCAGCAC	24	GCTCAATCCAGGCATCTTCT	86
Survivin	GGACCAACGCATCTCTACAT	25	CTGGTGCCACTTTCAGAGACA	87
TopoII a	AGTGGTGGAAATGGCTATG	26	CACCTCCACCTGTGGTTTAC	88
ZWint (MPP5)	CAGAACCAAGTGGCAGCTACA	27	AATGATGGTTGGAGGTGAG	89
Amphiregulin	CATTATGCTGCTGGATTGGA	28	TCATGGACATTTTCCCCACAC	90
APR (NOXA)	CCGGCAGAAACCTTCTGAATC	29	GTGCTGAGTTGGCACTGAAA	91
ATF3	GCTGGAATCAGTCACTGTCA	30	GCCTTCAGTTTCAGCATTCAC	92
bAPP	CTCGTTCTTGACAAAGTGCAA	31	TGTTTCAGAGCACACCTCTCG	93
BRI	AGAAAGAGCCTGGTGTGGTG	32	GCAAATAGGTTCCAGCCTTG	94
BTG1	CCGTGCTCTTCATCTCCAAG	33	TCCATAATCCATCCCCAAGA	95
BTG2	AACAGGCCACACACATACCTC	34	CTCTGCCAGGACCTCATTA	96
Calpain L2	GCAGGGATCTTTCACCTCCA	35	AGCTTGGGCAGTTGTCAATC	97
CD44	CTGCCGCTTTGCAGGTGTAT	36	TAGCAGGGATTCTGTCTGTG	98
C-JUN	ATGAGGAACCCGCATCGCTGCCT	37	GACCAAGTCTTCCCACTCGTG	99
Cyclin D1	AGGTCTGGAGGAAACAGAAG	38	AGCGTGTGAGGCGGTAGTAG	100
CYR61	GAAAGTTTCCAGCCCAACTG	39	TACACTGGCTGTCCACAAGG	101
ELF-1	TGTGGATCTAAGGGGAATGC	40	TCTTGCACCTGTGTGTTTC	102
EPLIN b	AGAAAGGGGACCTGACTGT	41	AAGATCCTCACCGTCTTGA	103
FAS (APO-1)	ATTGCTCAACAACCATGTCTG	42	GTTGCTGGTGTGAGTGTGCAAT	104
IGFBP-6	AACCGCAGAGACCAACAGAG	43	GACCCCAAGCACAGCTTTAT	105
Integrin b4	GTGACTGTCCCTCAGCAAT	44	CAGCAGGCACAGTACTTCCA	106
Jagged-1	TGCCTCTGTGAGACCAACTG	45	TCACAAATTCAGCCCATCCA	107
Keratin 18	CAGCATGAGCTTCACCACTC	46	CTCCTTCTCGTTCTGGATGC	108
LRP	AGATCAATTCAGGCCACCATC	47	CCGACAGCACATACACATCC	109



Gene	Sense (5'-3')	SEQ ID NO	Antisense (5'-3')	SEQ ID NO
MAC2-BP	ACCATGAGTGTGGATGCTGA	48	ACAGGGACAGGTTGAACCTGC	110
MAIPIN	CCCTATGCAAGGAATTGGA	49	CAAGCCTGTGGACTCATCCT	111
MBLL	TCCTGTTCCTTGGATTGGAC	50	AAAGTGGGCACTGGGATGAAG	112
MIC-1	CGGATACTCACGCCAGAAAGT	51	CACATGGTCACTTGCAACCTC	113
p21WAF	GGAAAGACCATGTGGACCTGT	52	ATGCCAGCACTCTTAGGAA	114
P-cadherin	GTGACAGCCACAGATGAGGA	53	TTTGGCCTCAAAAATCCAAAC	115
Prosaposin	CCAGAGCTGGACATGACTGA	54	GTCACTCCTTCACCAGGAA	116
PRSS6 (Kallikrein 7)	ATGGCAAGATCCCTTCTCCT	55	GGTCAGAGGGAAAGGTCACA	117
PRSS9 (Neurosin)	GGGGTCCCTTATCCATCCACT	56	GGGATGTTACCCCATGACAC	118
RNF3	AGACATCAAGGGGGAGACCT	57	CACCCAGAGGCAATGTTCTT	119
SOX-9	GGTTGTGGAGCTTTCTCA	58	TAGCCTCCCTCACTCCAAGA	120
Syndecan 4	TCGATCCGAGAGACTGAGGT	59	GGTTTCTTGCCCAAGGTCATA	121
TGFa	CAGGTCCGAAAACACTGTGA	60	AATTCTGTTGTGGGAGGTG	122
WIP1	CGACCTCGACTCACTCACA	61	ATGGGGAAGGAGTCATCACA	123
XBP-1	TAGCAGCTCAGACTGCCAGA	62	ACTGGGTCCAAGTTGTCCAG	124